Monoclonal anti-IL-1RAcP antibody

Monoclonal antibodies targeting IL-1RAcP effectively inhibit NFκB activity induced by IL-1 family cytokines, addressing the lack of therapeutic agents for NFκB pathway modulation, and show promise in treating diseases like osteoarthritis and cancer with reduced off-target effects.

JP7587549B2Active Publication Date: 2024-11-20SANOFI BIOTECH SAS
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022077834
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-12-17
Filing Date
2022-05-11
Publication Date
2024-11-20
Estimated Expiration
2036-06-23

AI Technical Summary

Technical Problem

Current monoclonal antibodies targeting IL-1RAcP do not effectively inhibit NFκB activity induced by IL-1 family cytokines, and there is a lack of effective therapeutic agents to modulate the NFκB pathway for treating diseases associated with its dysregulation.

Method used

Development of monoclonal antibodies that specifically bind to human and murine IL-1RAcP, inhibiting NFκB activity induced by IL-1α, IL-1β, IL-33, and IL-36, with reduced ADCC and C1q binding, and engineered Fc variants to minimize off-target effects.

Benefits of technology

The antibodies achieve significant inhibition of NFκB activity, offering potential therapeutic benefits for diseases such as osteoarthritis and cancer by modulating the NFκB pathway with reduced toxicity and improved specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587549000002
    Figure 0007587549000002
  • Figure 0007587549000003
    Figure 0007587549000003
  • Figure 0007587549000004
    Figure 0007587549000004
Patent Text Reader

Abstract

Provided are monoclonal anti-IL-1RAcP antibodies, methods for making and using same. [Solution] The present invention provides a monoclonal antibody against human IL-1RAcP, which comprises CDR1H, CDR2H and / or CDR3H, and CDR1L, CDR2L and / or CDR3L, each of which has a specific amino acid sequence, and which inhibits NFκB activity induced by IL-1RAcP; a method for producing the monoclonal antibody; use of the monoclonal antibody for the production of a pharmaceutical composition; and a method for treating an IL-1-mediated disease, which comprises administering a pharmaceutically effective amount of the antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a monoclonal anti-IL-1RAcP antibody, a method for producing the same and its use. do.

[0002] background Human IL-1RAcP (Q9NPH3(IL1AP_HUMAN, UniProtKB / Swiss-Prot)) is involved in signal transduction through the IL-1 family of receptors. The interleukin-1 receptor complex is an accessory protein required for I It is a heterodimer of IL-1R1 and IL-1RAcP. When IL-1 binds, it becomes IL- 1R1 associates with IL-1RAcP to form a functional signaling receptor complex, which This stimulates NFκB activity.

[0003] IL-33 and its receptors ST2 and IL-1RAcP also mediate NFκB activation. A complex with similar activity to the IL-1β / IL-1R1 / IL-1RAcP complex (IL-33 / ST2 / IL-1RAcP) is formed. IL-36(IL-36α(I IL-1F6), IL-36β (IL-1F8) and IL-36γ (IL-1F9) Their receptors, IL-36R and IL-1RAcP, also mediate NFκB activation. A complex (I IL-36 / IL-36R / IL-1RAcP).

[0004] International Publication No. 199623067 (WO199623067) describes a mouse IL-1 receptor Example 1: IL-1RAcP antibody specifically binds to a human accessory protein 5 and 16, generation of anti-human IL-1RAcP antibodies that neutralize the biological activity of IL-1 However, such an antibody is not disclosed in WO 1996 / 023636. 3067 (WO199623067) and Example 16, The description of the L-1-induced IL-6 assay is only hypothetical. DY and Charles A. Dinarello CA, J. Immunol. 1998;160:3170-3179, inhibits IL-1β activity but does not bind Polyclonal antibodies against domains II and III of mouse IL-1RAcP However, at higher concentrations of IL-1β (1000 pg / ml), Polyclonal antiserum to D10S cells did not inhibit proliferation of D10S cells (D10S is a mitogen-activated Subfemtomolar concentrations (attomolar concentrations) of IL-1β or IL-1α in the absence of Oren, a subclone of mouse D10.G4.1 helper T cells that proliferates to cole SF and Dinarello CA; Cytokine 1(198 9)14-22. Jaras M. et al., PNAS 107 (2010 ) 16280-16285 are the rabbit polyclonal anti-IL1RAcP antibody KMT-1 describes its use for killing CML stem cells. This antibody mediates ADCC by blocking IL1RA cP-independent induction is mediated by its rabbit Fc portion. "A potential future therapeutic IL1RAP targeting antibody could be used to target IL1RAP in normal hematopoietic cells," they wrote. "It is expected to show low toxicity to mouse IL-1RAcP." Polyclonal rabbit antibodies against les A. Dinarello, Journal of Biochemistry and Molecular Biology,Vol.40,No.4,July 2 This is also mentioned in pp.562-570 of 007.

[0005] Rabbit polyclonal antibody (a) that binds to mouse, rat and human IL1RAcP b8110) is commercially available from Abcam (Cambridge, Massachusetts, USA). Abcam's ab8109 binds only to human IL1RAcP. LAGURUNATHAN Y.et al.,Mol.Cancer Ther.7( 2008)3071-3080 are polyclonal rabbit anti-IL1R antibodies from Abcam. The use of AP antibodies for the identification of pancreatic tumor cells is described.

[0006] WO2002064630 also discloses IL-1R It concerns AcP and its uses, but no antibodies against IL-1RAcP have been described. International Publication No. 2004022718 (WO2004022718) and International Publication No. No. 09120903 (WO2009120903) is a novel antibody against CSF1R, IL13RA1, I L1RAP, IFNAR1, IL5R, INSR, IL1RL1, LTK and TACS It is theorized that antibodies against TD1 can be generated according to conventional techniques. However, no antibodies against IL-1RAcP are described here either. No. 1021014 (WO2011021014) and International Publication No. 2012098407 No. (WO2012098407) (U.S. Patent Application Publication No. 20140017167) (US20140017167)) is a polyclonal rabbit anti-human IL-1RAcP antibody. Regarding serum KMT-1 (see Jaras et al. 2010) and its uses. International Publication No. 2014100772 (WO2014100772) describes IL-1RAcP However, it does not have the function of stimulating NFκB activity. of functional signaling receptor complexes (IL-1β / IL-1R1 / IL-1RAcP, etc.) No inhibitory activity is described. No. 280955) also relates to IL-1RAcP and its uses, but again, No antibodies against 1RAcP have been described. 7390880) describes an N-terminal fragment of IL1RAcP, again No antibodies against AcP have been described.

[0007] International Publication No. 2004100987 (WO2004100987) describes a method for treating neointimal hyperplasia. Use of an interleukin I (IL-1) antagonist in the manufacture of a medicament for the treatment of The present invention relates to the use of IL-1 antagonists for the treatment of inflammatory bowel disease and neointimal hyperplasia. Anti-IL-1RAcP antibodies have been suggested as such antagonists, but further description is lacking. No. 2003026806 (US2003026806) has been filed. 806) relates to antibodies that bind to IL-1. O2002064630) also expressed IL-1 antagonists against the IL-1RAcP protein. IL-1 agonists for screening of IL-1RAcP antagonists Although the use of RAcP is mentioned, no such methods or antagonists are disclosed. not present.

[0008] International Publication No. 2003014309 (WO2003014309) describes a method for treating chronic myeloid leukemia. Use of IL-1RAcP protein for the treatment of diseases. International Publication No. 201302 No. 3015 (WO2013023015) relates to a method for determining the prognosis of AML and an early stem cell of AML by administering an agent that inhibits the expression or activity of IL-1RAcP in Regarding the therapeutic method, shRNA of IL-1RAcP is mentioned as such an agent. do.

[0009] Human NF-κB regulates the expression of several genes involved in inflammation, immune responses, and apoptosis. NFκB is a key regulator of cell proliferation and function, and its dysfunction is therefore associated with a number of important pathologies, including autoimmune diseases, neurodegeneration, and neurodegeneration. The NF-κB pathway is involved in the pathology of various diseases, including cancer, inflammation, and osteoarthritis. , an important target in the treatment of OA, and human IL1β-stimulated human NFκB Inhibition of activity may be important, for example, in the treatment of osteoarthritis. Inhibition of the signaling activity of the IL-1R1 / IL-1RAcP complex leads to the inhibition of human NFκB Monoclonal antibodies that modulate the pathway may be useful therapeutic agents in the treatment of a variety of human diseases. It is thought that this will happen.

[0010] However, it took approximately 10 days to generate functional monoclonal antibodies against human IL1RAcP. More than 15 years of unsuccessful attempts have led to the need for such a solution continuing today. do.

[0011] Summary of the Invention The present invention provides a monoclonal antibody against human IL-1RAcP. The antibodies according to the invention further bind to mouse IL-1RAcP.

[0012] The present invention relates to a monoclonal antibody against human IL-1RAcP, The present invention provides a monoclonal antibody that inhibits NFκB activity induced by cP. do.

[0013] The present invention provides monoclonal antibodies that specifically bind to human IL-1RAcP. Preferably, the antibody according to the invention further binds to mouse IL-1RAcP.

[0014] The present invention relates to a monoclonal antibody that specifically binds to human IL-1RAcP, A monoclonal antibody characterized by inhibiting L-1RAcP-induced NFκB activity Preferably, the antibody according to the present invention is directed to mouse IL-1RAcP. It also inhibits mouse NFκB activity.

[0015] The present invention relates to a monoclonal antibody against human IL-1RAcP, Inhibits NFκB activity stimulated by IL-1β, IL-33 and / or IL-36 The present invention provides a monoclonal antibody that inhibits human IL-1RAc. A monoclonal antibody against P that inhibits IL-1α-stimulated NFκB activity. The present invention provides a monoclonal antibody that is characterized by its ability to bind to human IL-1RAcP. It is a monoclonal antibody against IL-1β-stimulated NFκB activity. The present invention provides a monoclonal antibody characterized by:

[0016] The present invention relates to a monoclonal antibody against human IL-1RAcP, which is capable of stimulating IL33. The present invention provides a monoclonal antibody that inhibits stimulated NFκB activity. The present invention is a monoclonal antibody against human IL-1RAcP, which inhibits IL36-stimulated The present invention provides a monoclonal antibody that inhibits NFκB activity.

[0017] The present invention relates to a monoclonal antibody against human IL-1RAcP, IL-1R1 / IL-1RAcP, IL-1α / IL-1R1 / IL-1RAcP, IL -33 / ST2 / IL-1RAcP and IL-36 / IL-36R / IL-1RAcP The present invention is characterized in that it inhibits NFκB activity stimulated by a complex selected from the group consisting of The present invention provides a monoclonal antibody that

[0018] Preferably, the antibody according to the invention binds to mouse IL-1RAcP and -1RAcP-induced mouse NFκB activity is inhibited.

[0019] Preferably, the antibody according to the invention is administered at a concentration of 5 μg / ml (rabbit IgG isotype). , with a molecular weight of 150KD) and 0.5μg / ml of human IL-1α, IL-1β, IL-33 and / or IL-36 (molecular weights are determined by UniProtKB / Swiss-P rot) stimulated with 293T / 17 cell lysate (293T / 17[HEK 293T / 17] (ATCC® CRL-11268®), NFκB activity is increased by 70% or more compared to a similar assay without the antibody of the present invention; Preferably, the inhibition is 80% or more, more preferably 90% or more, and even more preferably 95% or more. It is characterized by:

[0020] Preferably, the antibody according to the invention is administered at a concentration of 5 μg / ml, IL-1α, IL-1β, IL-33 and / or IL-36 (molecular weight: UniPr otKB / Swiss-Prot) stimulated with each mouse cell line lysate. In the lysates, NFκB activity was measured against a similar assay without the antibody according to the invention. 70% or more, preferably 80% or more, preferably 90% or more, more preferably 95% or more It is characterized by its ability to inhibit the above.

[0021] Preferably, the antibody according to the invention comprises a wild-type human IgG Fc region. At least 20% of the ADCC induced by the antibody, preferably at least 10% The antibodies are characterized by exhibiting reduced ADCC to:

[0022] Preferably, the antibody according to the invention comprises a wild-type IgG Fc region. Reduced human FcγRIIIA and / or FcγRIIA and / or or FcγRI, wherein the affinity induced by said antibody according to the invention The ADCC induced by the antibody according to the present invention containing the Fc region of wild-type human IgG. The present invention is characterized in that the ADCC caused by the antibody is reduced by at least 20%.

[0023] Preferably, the antibodies according to the invention have a specific function in inhibiting IL-1 activation, such as ADCC and / or reduced C1q binding. In particular, the present invention relates to a method for the production of Fc domains of wild-type human IgG. and an antibody according to the invention comprising a variant, said Fc variant comprising a 1 at position Pro329. and at least one further amino acid substitution, The residues are numbered according to the EU index of Kabat. In addition, the antibody according to the present invention has a structure similar to that of the antibody according to the present invention, which comprises the Fc region of a wild-type IgG. and human FcγRIIIA and / or FcγRIIA and / or F and wherein the antibody according to the invention is induced ADCC is induced by antibodies according to the invention comprising the Fc region of wild-type human IgG ADCC is reduced by at least 20%.

[0024] In a specific embodiment, the Pr o329 is glycine or arginine, or proline 329 of Fc and FcγR The Fcγ receptor is formed between tryptophan residues Trp87 and Trp110 of Fcγ receptor III. Substituted with an amino acid residue large enough to disrupt the proline sandwich within the receptor boundary. (Sondermann et al.: Nature 406, 267-273( In a further aspect of the invention, the Fc variant At least one additional amino acid substitution is selected from the group consisting of S228P, E233P, L234A, L 235A, L235E, N297A, N297D or P331S. In yet another embodiment, the at least one further amino acid substitution The substitutions were made using L234A and L235A of the Fc region of human IgG1 or L236A of the Fc region of human IgG4. The regions are S228P and L235E.

[0025] In another embodiment of the invention, an antibody according to the invention is provided which is a wild-type human I In comparison with the antibody according to the present invention which comprises the Fc region of human receptors FcγI, FcγIIA and C1q. In yet another embodiment of the invention, the antibody according to the invention is human IgG1 or contains the Fc region of IgG4.

[0026] A further aspect of the invention is directed to a method for the preparation of a glycoprotein comprising administering to a subject an Fc variant of a wild-type human IgG Fc region. an antibody having Pro329 of the Fc region of human IgG substituted with syn, The residues are numbered according to the EU index of Kabat, and are Antibodies according to the invention exhibiting reduced affinity for cγRIIIA and FcγRIIA ADCC induced by the antibody according to the present invention comprising the Fc region of wild-type human IgG and / or inhibiting ADCC by at least 20% of the It is used to make controlled adjustments.

[0027] Another embodiment of the present invention is an Fc variant of the Fc region of wild-type human IgG, an antibody having Pro329 of the Fc region of human IgG substituted with syn, The Fc variant comprises L234A and L235A of the Fc region of human IgG1 and human At least two additional amino acids at S228P and L235E in the Fc region of IgG4 The residues are numbered according to the EU index of Kabat. and exhibits reduced affinity for human FcγRIIIA and FcγRIIA. Induced by the antibody according to the present invention comprising the Fc region of wild-type human IgG and / or for down-regulating ADCC by at least 20% of the ADCC induced. or for down-regulating ADCC.

[0028] In another embodiment of the invention, an individual with a disease is treated with human I and treating said individual with an antibody according to the invention which has Pro329 of the Fc region of gG. wherein the residues are numbered according to the EU index of Kabat, The antibody according to the present invention is an antibody according to the present invention comprising the Fc region of wild-type human IgG. significantly reduced binding of FcγRIIIA and / or FcγRIIA compared to controls The method of treatment comprises administering to the individual an effective amount of the antibody according to the invention. A method is provided that includes:

[0029] In yet another embodiment of the invention, the antibody according to the invention used in the method , L234A and L235A of the Fc region of human IgG1 or the Fc region of human IgG4 It contains at least two additional amino acid substitutions at S228P and L235E of.

[0030] The present invention preferably relates to an antibody against human IL-1RAcP, ) region corresponds to a VH region selected from the group consisting of VH regions of SEQ ID NO: 1 to SEQ ID NO: 77 The present invention provides antibodies that are at least 90% identical to the above sequence.

[0031] The present invention preferably relates to an antibody against human IL-1RAcP, ) The VL region is selected from the group consisting of the VL regions of SEQ ID NO: 78 to SEQ ID NO: 154. The present invention provides an antibody that is at least 90% identical to

[0032] The present invention preferably relates to an antibody according to the present invention, the VH region of which is represented by SEQ ID NO: 1+n VH region is at least 90% identical to the VL region of SEQ ID NO: 78+n wherein n is a number selected from the group consisting of 0 to 76. The present invention provides an antibody characterized by:

[0033] The present invention preferably relates to an antibody according to the present invention, the VH region of which is represented by SEQ ID NO: 1+n VH region of SEQ ID NO: 78+n, and the VL region of SEQ ID NO: 78+n. wherein n is a number selected from the group consisting of 0 to 76. Characterized antibodies are provided.

[0034] The present invention preferably relates to an antibody according to the invention, which has the sequence of SEQ ID NO: 155+n CDR1H region, CDR2H region of SEQ ID NO: 232+n, and CDR3H region of SEQ ID NO: 309+n The VH region is selected from the group of VH regions including DR3H regions, wherein n is 0 to 7. The present invention provides an antibody characterized in that the number is selected from the group consisting of 6.

[0035] The present invention preferably relates to an antibody according to the present invention, which has the sequence of SEQ ID NO: 386+n CDR1L region, CDR2L region of SEQ ID NO: 463+n, and CDR3L region of SEQ ID NO: 540+n The VL domain is selected from the group of VL domains including DR3L domains, wherein n is 0 to 7. The present invention provides an antibody characterized in that the number is selected from the group consisting of 6.

[0036] The present invention preferably relates to an antibody according to the invention, which has the sequence of SEQ ID NO: 155+n CDR1H region, CDR2H region of SEQ ID NO: 232+n, and CDR3H region of SEQ ID NO: 309+n a VH region selected from the group of VH regions comprising a DR3H region, and the antibody has the sequence The CDR1L region of SEQ ID NO: 386+n, the CDR2L region of SEQ ID NO: 463+n, and the CDR3L region of SEQ ID NO: The VL region comprises a VL region selected from the group consisting of VL regions comprising the CDR3L region of No. 540+n, and n is a number selected from the group consisting of 0 to 76. .

[0037] The present invention preferably relates to an antibody according to the invention, the antibody P013.S.01.BB 03, P013.S.01.B.A05, P013.S.01.B.C04, P013. S.01.B.H01, P013.S.01.B.D03, P013.S.01.BE 02, P013.S.02.B.A04, P013.S.02.B.A05, P013. S.02.B.A02, P013.S.02.B.D03, P013.S.02.BH 01, P013.S.02.B.F01, P013.S.02.B.B04, P013. S.02.B.C02, P013.S.02.B.B05, ​​P013.S.02.BA 03, P013.S.02.B.H03 ​​and P013.S.02.B.G05 The antibody is selected from the group consisting of CDR1, CDR2 and CDR3 regions. The present invention provides an antibody comprising a VH region and a VL region comprising the VH region and the ....

[0038] The present invention preferably relates to an antibody according to the invention, the antibody P013.S.01.BB 03, P013.S.01.B.A05, P013.S.01.B.C04, P013. S.01.B.H01, P013.S.01.B.D03, P013.S.01.BE 02, P013.S.02.B.A04, P013.S.02.B.A05, P013. S.02.B.A02, P013.S.02.B.D03, P013.S.02.BH 01, P013.S.02.B.F01, P013.S.02.B.B04, P013. S.02.B.C02, P013.S.02.B.B05, ​​P013.S.02.BA 03, P013.S.02.B.H03 ​​and P013.S.02.B.G05 The antibody is selected from the group consisting of CDR1, CDR2 and CDR3 regions. The present invention provides an antibody comprising a VH region and a VL region comprising the VH region and the ....

[0039] The present invention preferably relates to an antibody that specifically binds to human IL-1RAcP, P013.S.01.B.B03, P013.S.01.B.A05, P013.S.0 1.B.C04, P013.S.01.B.H01, P013.S.01.B.D03, P013.S.01.B.E02, P013.S.02.B.A04, P013.S.0 2.B.A05, P013.S.02.B.A02, P013.S.02.B.D03, P013.S.02.B.H01, P013.S.02.B.F01, P013.S.0 2.B.B04, P013.S.02.B.C02, P013.S.02.B.B05, P013.S.02.B.A03, P013.S.02.B.H03 ​​and P013.S IL-1RA, which binds to the same epitope as an antibody selected from the group consisting of .02.B.G05 The present invention provides an antibody that inhibits cP-induced NFκB activity.

[0040] The present invention preferably relates to an antibody according to the present invention, which is a monoclonal rabbit antibody, The present invention provides an antibody which is a rabbit / human chimeric antibody or a humanized rabbit antibody.

[0041] The present invention is characterized by inhibiting NFκB activity stimulated by IL1β according to the present invention. A method for producing a monoclonal rabbit antibody against human IL-1RAcP, comprising: i) a number of samples obtained from the rabbits after immunization with IL-1RAcP Isolating antibody-producing single cells; ii) measuring binding to IL-1RAcP in the supernatants of the single cells separately; Top, iii) the supernatant exhibits binding to human and mouse IL-1RAcP and NFκB activity stimulated by IL-1β, IL-33 and / or IL-36 selecting a single cell if iv) isolating antibodies having the characteristics of step iii) from the selected cells. Top The present invention provides a manufacturing method characterized by the above.

[0042] Preferably, the rabbit antibody producing single cells are rabbit hybridoma single B cells.

[0043] The present invention relates to an antibody that binds to human IL-1RAcP and is capable of inhibiting IL-1α, IL-1β, IL-33, and the like. and / or a monoclonal antibody that inhibits IL-36-stimulated NFκB activity A method for producing heron antibodies is provided.

[0044] The present invention relates to a method for producing a monoclonal rabbit antibody according to the present invention, comprising: After immunization with the antigen, binding to human IL-1RAcP and IL-1α, IL-1β and inhibition of NFκB activity stimulated by IL-33 and / or IL-36. In the case of the invention, antibody-producing single cells, preferably B cells, are isolated from the animal. Isolate rabbit hybridoma cells from the rabbit or from the rabbit. The present invention provides a method comprising the steps of:

[0045] The present invention preferably provides the use of an antibody according to the present invention for the manufacture of a pharmaceutical composition. do.

[0046] The present invention relates to antibody-producing rabbit single cells, preferably single B cells or rabbit hybridomas. The supernatant of human IL-1RAcP and IL-1α according to the present invention , NFκB activity stimulated by IL-1β, IL-33 and / or IL-36 A supernatant is provided which is characterized as inhibiting the

[0047] The present invention preferably relates to antibody-producing rabbit single cells, preferably single B cells, according to the present invention. or a rabbit hybridoma cell supernatant that binds to human IL-1RAcP; The present invention provides a method for stimulating the immune system by the administration of IL-1α, IL-1β, IL-33 and / or IL-36. Inhibits stimulated NFκB activity, binds to human IL-1RAcP, and inhibits IL-1α, I Inhibition of NFκB activity stimulated by IL-1β, IL-33 and / or IL-36 If the antibody exhibits the properties according to the invention, A supernatant is provided which is characterized in that it is isolated from the cells.

[0048] The present invention relates to a method for producing a monoclonal rabbit antibody according to the present invention, comprising the steps of: i) a number of antibodies obtained from the rabbit after immunization of the rabbit with the target antigen; isolating said antibody-producing single cells; ii) measuring binding to IL-1RAcP in the supernatants of the single cells separately; Top and iii) the supernatant exhibits binding to human and mouse IL-1RAcP and is suitable for use in the present invention Stimulated by IL-1α, IL-1β, IL-33 and / or IL-36 selecting a single cell if NFκB activity is inhibited; iv) isolating the antibody from the selected cells if the antibody exhibits the characteristics according to step iii). and isolating The present invention provides a manufacturing method characterized by the above.

[0049] Preferably, the antigen used for immunization (IL-1RAcP) is a combination of said antigen and A fusion polypeptide consisting of a human Fc polypeptide. In step i), CFA is used as an adjuvant. and IFA are used together as adjuvants.

[0050] Preferably, in step ii) the B cells are isolated from rabbit blood. Preferably, the cells are isolated as PBMCs and depleted of macrophages. The antigen used for the isolation of B cells in this study is the target protein IL-1RAcP. or a functional fragment thereof, preferably an extracellular domain thereof or a portion thereof, Cells that present antigens, etc.

[0051] Preferably in step iii) the cells secrete immunoglobulins, preferably IgG. The single B cells are preferably separated by FACS. and treating with feeder cells prior to carrying out step iv).

[0052] Preferably, in step iii), the antibody specifically binds to human IL-1RAcP, and The antibody that inhibits IL-1RAcP-induced NFκB activity is secreted. Single B cells are isolated. Preferably, in step iii), human and mouse I IL-1RAcP-specific binding and mouse NF-α-IL-1RAcP-induced Single B cells are isolated that are characterized by secreting antibodies that further inhibit κB activity.

[0053] Preferably in step iii) IL-1α, IL-1β, IL-33 and / or or a human IL-36-stimulated NFκB activity. Single B cells are isolated that are characterized by secreting antibodies against -1RAcP. In step iii), a human IL-1α-stimulated NF-κB activity is inhibited. Single B cells are isolated that are characterized by secreting antibodies against -1RAcP. In step iii), a human IL-1β inhibitor is used to inhibit IL-1β-stimulated NF-κB activity. Single B cells are isolated that are characterized as secreting antibodies against -1RAcP.

[0054] Preferably, in step iii), IL33-stimulated NFκB activity is inhibited. Single B cells are isolated that are characterized by secreting antibodies against human IL-1RAcP. Preferably, in step iii), IL36-stimulated NFκB activity is inhibited. Single B cells are isolated that are characterized by secreting antibodies against human IL-1RAcP. .

[0055] Preferably in step iii) and IL-1β / IL-1R1 / IL-1RA cP, IL-1α / IL-1R1 / IL-1RAcP, IL-33 / ST2 / IL-1R AcP and IL-36 / IL-36R / IL-1RAcP. We isolated an antibody against human IL-1RAcP that inhibits NFκB activity stimulated by IL-1R. A single B cell is isolated that is characterized as secreting B cells.

[0056] Preferably, in step iii), the antibody binds to mouse IL-1RAcP and is a mouse IL-1RAcP antibody. Characterized by secreting antibodies that inhibit IL-1RAcP-induced mouse NFκB activity A single B cell is isolated.

[0057] Preferably, in step iii), the concentration is 5 μg / ml (rabbit IgG isotype). The antibody has a molecular weight of 150KD and contains 0.5μg / ml of human IL-1α, IL-1 β, IL-33 and / or IL-36 (molecular weights are given by UniProtKB / Swiss -Prot) stimulated 293T / 17 cell lysate (293T / 17[H EK 293T / 17 (ATCC® CRL-11268®) NFκB activity was increased by more than 70% compared to a similar assay without the antibody of the present invention. In addition, the inhibition is preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more. A single B cell is isolated that is characterized as secreting an antibody that inhibits the production of the antibody.

[0058] Preferably, in step iii), the concentration is 5 μg / ml, and the concentration is 0.5 μg / ml. Mouse IL-1α, IL-1β, IL-33 and / or IL-36 (molecular weights are listed in the Un Each mouse cell was stimulated with NFκB activity was assayed in cell line lysates using a similar assay without the antibody of the invention. 70% or more, preferably 80% or more, preferably 90% or more, more preferably 9 Single B cells are isolated that are characterized as secreting antibodies that inhibit by 5% or more.

[0059] Preferably, in step iii), lucifϊ is expressed under the control of an NF-κB reporter gene. In 293T / 17 cells transfected with IL-1, mol / l IL-1α, IL-1β, IL-33 and / or IL-36, e.g., antibody XX or Single B cells are isolated that are characterized by their ability to secrete antibodies upon stimulation with more.

[0060] Preferably, the method according to the invention comprises in step iii) is carried out on human IL-1RAcP Isolating single B cells that contain mRNA encoding the VH region of a specifically binding antibody It is characterized by:

[0061] Preferably, the antibody is a rabbit monoclonal antibody.

[0062] Preferably, antibodies produced by single B cells are detected, preferably by ELISA. It is tested for its specific binding to the respective antigen.

[0063] Preferably, the antibody is tested for whether it specifically binds to IL-1RAcP. Preferably, the antibody is recombinantly produced using the nucleic acid and and / or polypeptide sequences.

[0064] Preferably, in step iii), the VH region of SEQ ID NO: 1+n is at least 90% The mRNA encoding the VH region of the IL-1RAcP-specific antibody as defined in FIG. IL-1 NA and at least 90% identical to the VL region of SEQ ID NO: 78+n. A single B cell was selected that contained mRNA encoding the VL region of an antibody that specifically binds to RAcP. where n is a number selected from the group of 0 to 76.

[0065] According to the present invention, "n is a number selected from the group of 0 to 76" means 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 1 9, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 , 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 5 9, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72 , 73, 74, 75 and 76. The number "n" according to the present invention are identical for the same antibody, its heavy and light chains, its variable regions and its CDR regions. This means that

[0066] The present invention relates to a method for the production of a compound that specifically binds to the amino acid sequences described herein. Includes monoclonal antibodies.

[0067] The heavy chain variable (VH) region of the IL-1RAcP specific antibody preferably comprises: At least one VH region selected from the group consisting of the VH regions of SEQ ID NO: 1 to SEQ ID NO: 77 The light chain variable (VL) region of the HER-specific antibody is Preferably, the VL region is selected from the group consisting of the VL regions of SEQ ID NO: 78 to SEQ ID NO: 154. The present invention provides a method for the preparation of a VL region comprising the steps of: The antibody preferably has a VH region that is at least 90% identical to the VH region of SEQ ID NO: 1+n. and the VL region is at least 90% identical to the VL region of SEQ ID NO: 78+n. Here, n is a number selected from the group consisting of 0 to 76. The antibody according to the present invention preferably has a VH region selected from the group consisting of the VH regions of SEQ ID NO: 1+n. and wherein the VL region is selected from the group consisting of the VL regions of SEQ ID NO: 78+n, In the present invention, n is a number selected from the group consisting of 0 to 76. The antibody is preferably selected from the group consisting of the antibodies listed in FIG. It comprises a VH region and a VL region, each of which includes a CDR1 region, a CDR2 region, and a CDR3 region. The antibody according to the invention is preferably characterized in that the antibody has the sequence of SEQ ID NO: 155+n. DR1H region, CDR2H region of SEQ ID NO: 232+n, and CDR3H region of SEQ ID NO: 309+n R3H region, wherein n is 0 to 76. The number is selected from the group consisting of:

[0068] The antibody according to the invention preferably comprises the CDR1L region of SEQ ID NO: 386+n, The CDR2L region of SEQ ID NO: 463+n and the CDR3L region of SEQ ID NO: 540+n. wherein n is selected from the group consisting of 0 to 76. It is characterized in that it is a selected number.

[0069] The antibody according to the invention preferably comprises the CDR1H region of SEQ ID NO: 155+n, The CDR2H region of SEQ ID NO: 232+n and the CDR3H region of SEQ ID NO: 309+n. and the antibody comprises a VH region selected from the group of VH regions comprising SEQ ID NO: 386+n CDR1L region, CDR2L region of SEQ ID NO: 463+n, and CDR3L region of SEQ ID NO: 540+n The VL domain is selected from the group of VL domains including DR3L domains, wherein n is 0 to 7. 6.

[0070] The invention also provides compositions, B cells, methods of using and producing antibodies according to the invention. do.

[0071] The antibody according to the invention is preferably a humanized or chimeric version of said antibody. Preferably, the antibody according to the invention is characterized in that it is a non-human sequence, a human sequence, or The humanized sequences (e.g., framework sequences and / or constant domain sequences) are Preferably, the antibody of the present invention comprises an antigen-binding sequence derived from a rafted rabbit donor. The antibody may comprise rabbit V regions or rabbit CDR regions and human C regions and / or framework regions. Preferably, the rabbit VL region contains rabbit light chain CDRs or a human frame. The constant region is fused to a human kappa light chain constant region. The rabbit VH region or human framework region may be a human constant region, preferably an IgG1 Preferably, the present invention relates to a chimeric or humanized rabbit antibody comprising: Contains a serine instead of a cysteine ​​at amino acid positions 75-85 in the variable light chain VL. The present invention relates to an antibody comprising

[0072] The present invention also provides a pharmaceutical composition comprising the antibody according to the present invention. The present invention also provides a use of an antibody according to the present invention for the manufacture of a pharmaceutical composition. Also for the treatment of patients in need of treatment, preferably in the treatment of cancer. The present invention also provides an antibody according to the present invention for the treatment of breast cancer, colon cancer, lung cancer or pancreatic cancer. The present invention also provides an antibody according to the present invention for treating a patient in need of treatment. and the preparation of a medicament for the treatment of a patient in need of treatment, preferably in the treatment of cancer. The present invention also provides the use of the antibody according to the present invention for the treatment of breast cancer, colon cancer, lung cancer or The present invention also provides a method for the manufacture of a medicament for the treatment of pancreatic cancer. Preferably in the treatment of cancer, preferably in the treatment of breast cancer, colon cancer, lung cancer or pancreatic cancer. The present invention provides an antibody according to the present invention for use in treating a patient in need of such treatment. do.

[0073] The present invention also provides a nucleic acid encoding an antibody according to the present invention. A nucleic acid according to the invention for the expression of an antibody according to the invention in a host cell or a eukaryotic host cell. The present invention also provides an expression vector comprising the nucleic acid according to the present invention. The present invention also provides a prokaryotic or eukaryotic host cell comprising an antibody according to the invention. The method comprises the steps of: and recovering said antibody from said cells or cell culture supernatant. A method is provided.

[0074] Preferably, the antibodies of the invention are antagonistic antibodies.

[0075] The sequence of the antibody comprising the VH and / or VL regions or the CDR regions is shown in FIG. As shown in.

[0076] Detailed Description of the Invention The term "rabbit" according to the present invention refers to an animal belonging to the taxonomic order Lagomorpha, family (Legus and Hare). and rabbits) and pikas (Ochotona ochotona), preferably animals of the genus Hare. It means.

[0077] The term "antibody" refers to various forms of antibody structure, including but not limited to the The present invention encompasses whole antibodies and antibody fragments, provided they exhibit the properties according to the invention. Antibodies are produced primarily by rabbit B cells and are expressed as IL-1RAcP Thus, the antibody according to the invention binds to the antigen-binding portion, preferably the three VH and / or a VL region thereof comprising three VL CDRs. It specifically binds to IL-1RAcP.

[0078] The term "rabbit monoclonal antibody" according to the present invention refers to a monoclonal antibody produced by immunizing rabbits. The present invention also provides a method for the production and isolation of a monoclonal antibody from the antigen-producing rabbit cells. Such antibodies, preferably those which have been further modified, may be used as long as the characteristic properties of the antibodies described above are maintained. The antibody may be a humanized antibody, a chimeric antibody, a fragment thereof or a recombinant antibody further engineered to Preferably, the antibody is an antibody produced by the rabbit B cells or rabbit hyperplasia. It is derived from bryomycin cells.

[0079] The term "antibody-producing cells" according to the present invention refers to antibody-producing rabbit B cells, preferably B cells or means rabbit hybridoma cells.

[0080] A "native antibody" typically consists of two identical light (L) chains and two identical heavy (H) chains. It is a heterotetrameric glycoprotein composed of 1 light chain. Each light chain binds to one heavy chain. They are linked by covalent disulfide bonds, but the number of disulfide bonds varies among different immunoglobulins. The heavy chains of each purine isotype vary. Each heavy chain has multiple, spaced intrachain disulfide bridges at one end. Each light chain has a variable domain (VH) followed by a number of constant domains. The light chain has a variable domain (VL) at one end and a constant domain at the other end. The light chain variable domain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the first constant domain of the heavy chain. Specific amino acid residues are aligned in the light and heavy chain variable domains. It is thought to form the boundary between

[0081] The term "VL (or VH) region" has the same meaning as a VL (or VH) domain. The antibodies according to the invention have properties that may differ in their primary form from simple germline antibodies. Without being bound by theory, it is believed that the binding of antigens to germline antibodies occurs largely This can result in significant structural rearrangements, whereas the unbound state of the mature antibody is Thus, the mature form of an antibody is likely to be closer to the original state than the germline form. Germline antibodies have a rigid structure. Therefore, they are more conformationally flexible. This may result in slower binding rates (see, e.g., Wedemayer GJ et al.,Science.1997 Jun 13;276(5319):166 5-9; Structural insights into the evolution ion of an antibody combining site). A less flexible structure of the antibody may be improved, for example, by being more soluble or less likely to aggregate. The physicochemical properties of the antibodies according to the invention can be improved, resulting in improved therapeutic properties. The antibody according to the present invention identified from human B cells is an antibody having a naturally occurring variable region. "Naturally occurring" means, according to the present invention, that such antibodies may occur naturally in rabbits. This means having a variable region that is identical in amino acid sequence to the sequence of the variable region. The antibody according to the present invention may be further modified, preferably a rabbit antibody, a humanized antibody. As long as the characteristic properties of the chimeric antibodies, their fragments, or the present invention are maintained, The antibody may be further genetically engineered and recombinantly produced. Preferably, the antibody according to the invention is a rabbit antibody. It is an antibody.

[0082] Preferably, the primary form of the antibody is human IL-1RAcP and murine IL-1RA. It specifically binds to cP.

[0083] The term "single cell supernatant" according to the present invention refers to the supernatant of antibody-producing rabbit single cells, preferably B cells. Or the supernatant of the culture of rabbit hybridoma cells. Such a supernatant is used in the present invention. Thus, the Fc portion / constant portion is a monoclonal antibody that is It is in a silicified state.

[0084] According to the present invention, the term "Fc receptor" or "FcR" refers to a human Fc receptor that binds to the Fc region of an antibody. FcR refers to the receptor that binds IgG antibodies and is involved in the regulation of FcγRI, FcγRII and Fcγ Receptors of the RIII subclass, including allelic variants and selective serotypes of these receptors. FcγRII receptors include FcγRIIA ("activating receptor agonist") and FcγRII ("activating receptor agonist"). ") and FcγRIIB ("inhibitory receptor"), which are primarily involved in the cytoplasmic The activating receptor FcγRIIA has a similar amino acid sequence that differs in the FcγRIIA domain. It contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB binds to the immunoreceptor tyrosine vector in its cytoplasmic domain. It contains an inhibitory transcription motif (ITIM) (Daeron, M., Annu. Rev. Immunol. (See review in Unol. 15:203-234 (1997)). D16a) affects ADCC. FcR is a marker for ADCC. Annu. Rev. Immunol 9:457-92 (1991), Capel et al. al, Immunomethods 4:25-34 (1994), and de Ha as et al, J.Lab.CHn.Med.126:330-41 (1995). All these other FcRs are referred to herein by the term " The term also encompasses the FcRs that are responsible for transferring maternal IgG to the fetus. It contains the neonatal receptor FcRn (Guyer et al., J. Immunol. 117: 587 (1976) and Kim et al., J. Immunol. 24:249 (1 994)), affecting slower catabolism and thus a longer half-life.

[0085] The "constant domain (constant part)" is not directly involved in binding of an antibody to an antigen, but is The heavy chain constant region corresponding to human IgG1 is called the γ1 chain. The heavy chain constant region corresponding to IgG3 is called the γ3 chain. The human constant γ heavy chain is ,EAet al.,Sequences of Proteins of Imm unological interest,5th ed.,Public Healt h Service, National Institutes of Health, Bethesda, M.D. (1991) and Brueggemann, M., et al. l.,J.Exp.Med.166(1987)1351-1361;Love,TW .,et al.,Methods Enzymol.178(1989)515-52 7. The constant domains of IgG1 or IgG3 types are The "Asn297" according to the present invention is glycosylated in the Fc region. Refers to the amino acid asparagine located at about position 297, based on slight sequence variations in the antibody. Asn297 is located a few amino acids upstream or downstream (usually +3 or less) Sometimes it is found in.

[0086] Glycosylation of human IgG1 or IgG3 can be achieved by up to two Gal (galactose) residues. Asn is the glycosylation site of core-fucosylated biantennary complex oligosaccharides terminating in the Asn group These structures are classified as G0, G1(α1,6 or α1,3) or G2 glycan residues (Raju, T.S., BioP process International 1(2003)44-53). Antibody Fc part The glycosylation of CHO type is, for example, Jugate J.14(1997) 201-207. Cell-mediated effector functions such as ADCC of antibodies are described by Umana, P., et al. ,Nature Biotechnol.17(1999)176-180,Naoko Yamane-Ohnuki and Mitsuo Satoh,MAbs.200 9;1(3):230-236 and U.S. Pat. No. 6,602,684 (US6, 602,684), International Publication No. WO2005 / 044859 ), International Publication No. 2004 / 065540 (WO2004 / 065540), International Publication No. As described in WO2007 / 031875, This can be further enhanced by engineering the oligosaccharides attached to the Fc region (defucosylation). Such methods can be used, for example, to treat host cells with reduced inherent α-1,6 fucosylation capacity, e.g. For example, Lec13, a variant of CHO cells partially defective in GMD function, or YB 2 / 0, a rat-rat hybridoma with naturally reduced FUT8 activity Use of cells and small interfering RNA (siRNA) against α-1,6 fucosylation-related genes Introduction of β-1,4-N-acetylglucosaminyltransferase (GnTIII) and Golgi α-mannosidase II (ManII),58,83,84 and and disruption of genomic loci responsible for α-1,6-fucosylation.

[0087] As used herein, the term "antibody effector function" or "effector function" refers to provided by the Fc effector domain of IgG (e.g., the Fc region of an immunoglobulin) Such functions include, for example, the function of the Fc effector domain in promoting phagocytic activity or by binding to Fc receptors on immune cells that have cytolytic activity or by binding to Fc receptors on immune cells that have cytolytic activity The effector domains may be exerted by binding to components of the complement system. The effector functions are ADCC, ADCP and CDC. An intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Antibody fragments refer to molecules other than antibodies. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabody, single-chain antibody Antibody fragments, single chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments. The antibody includes a target antibody.

[0088] An "antibody that binds to the same epitope" as a reference antibody is a competitive antibody that inhibits the binding of the reference antibody to the antigen. refers to an antibody that blocks by 50% or more in a combined assay, whereas a reference antibody It refers to an antibody that blocks the body's binding to its antigen by 50% or more in a competitive assay. A typical competitive assay is defined herein.

[0089] "Antibody-dependent cell-mediated cytotoxicity" and "ADCC" are non-specific cytotoxicity that targets FcR-expressing cells. Cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognizes antibodies bound to target cells and subsequently induces lysis of the target cells. ADCC refers to a cell-mediated response that induces ADCC. The primary cells that mediate ADCC, i.e., NK cells, are Fc γRIII, whereas monocytes express only FcγRI, FcγRII and FcγRIII. FCR expression in hematopoietic cells was reported by Ravetch, and Kinet, Ann As summarized in Table 3 on page 464 of U. Rev. Immunol 9 (1991) 457-492. The terms "antibody-dependent cellular phagocytosis" and "ADCP" refer to the phagocytosis of cells coated with antibodies. phagocytic proteins that bind, either in whole or in part, to the Fc region of immunoglobulins The process of uptake by immune cells (e.g. macrophages, neutrophils, and dendritic cells) Point.

[0090] C1q is a polypeptide that contains a binding site for the Fc region of immunoglobulins. 1q, together with two serine proteases C1r and C1s, constitutes the C1 complex, the complement Human C1q forms the first component of the cytokine-dependent cytotoxicity (CDC) pathway. It can be commercially purchased from EL (San Diego, Calif.).

[0091] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major antibody classes: IgA, IgD, IgE, IgG and IgM. Some of these are further subdivided into subclasses (isotypes), e.g., IgG1, IgG2, IgG 3. They can be divided into IgG4, IgA1 and IgA2. The heavy-chain constant domains that correspond to the α, β, ε, γ, and μ, respectively.

[0092] "Effector functions" are ascribed to the Fc region of antibodies, which vary with antibody isotype. These biological activities include, but are not limited to, Clq binding and complement-dependent activation. mediated cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC) , phagocytosis (ADCP), downregulation of cell surface receptors (e.g., B cell receptor) and B cell As used herein, "reduced effector function" refers to a specific Effector functions, such as ADCC or CDC, are determined using a control (wild-type Fc region) "a polypeptide having a structure similar to that of the polypeptide having the formula (I)" is reduced by at least 20%; As used herein, "significantly reduced effector function" refers to a specific effector function. A function, such as ADCC or CDC, is at least 50% greater than in a control. This refers to a reduction in the

[0093] An "effective amount" of an agent, e.g., a pharmaceutical formulation, is an amount that provides the desired treatment at the required dosage for the required period of time. Refers to an amount effective to achieve a desired outcome or preventive outcome.

[0094] As used herein, the term "Fc region" refers to an immunoglobulin that contains at least a portion of the constant region. The term is used to define the C-terminal region of a native sequence Fc heavy chain. In one embodiment, the Fc region of a human IgG heavy chain is extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region can be either present or absent. Unless otherwise specified herein, the amino acid residues in the Fc region or constant region The numbering is based on Kabat, et al., Sequences of Proteins. ns of Immunological Interest,5th Ed.Publ ic Health Service,National Institutes of EU numbering system as described in the Department of Health, Bethesda, MD (1991) The "variant Fc region" is based on the EU index. At least one "amino acid modification" as defined herein renders the polypeptide "native" or The variant comprises an amino acid sequence that differs from that of the "wild type" sequence of the Fc region. The Fc region has a reduced length relative to the native sequence Fc region or the Fc region of the parent polypeptide. At least one amino acid substitution, e.g., in the native sequence Fc region or in the Fc region of a parent polypeptide. In the c region, there are about 1 to about 10 amino acid substitutions, preferably about 1 to about 5. The Fc region of the variant herein preferably has an amino acid substitution at the native and / or the Fc region of the parent polypeptide. and most preferably has at least about 90% homology thereto, More preferably, it has at least about 95% homology therewith.

[0095] As used herein, the term "Fc variant" refers to a polypeptide that contains modifications in the Fc domain. The Fc variants of the present invention are defined by the amino acid modifications that compose them. Thus, for example, P329G represents a glycine-proline replacement at position 329 relative to the parent Fc polypeptide. lysine substituted Fc variants, where numbering is according to the EU index. The identity of the wild-type amino acid may be unspecified, in which case the above-mentioned diversity The structure is designated P329G. For all positions discussed in this invention, the numbering is , EU Index. EU Index or Kabat or EU The EU index in the numbering scheme refers to the EU antibody numbering (Ede lman,et al.,Proc Natl Acad Sci USA 63(19 69) 78-85, which are incorporated herein by reference in their entirety. Modifications include additions, deletions, Substitutions may be of naturally occurring and non-naturally occurring amino acids. The variants may include unnatural amino acids. ,586,207 (US Pat. No. 6,586,207), International Publication No. 98 / 48032 (WO98 / 48032), International Publication No. 03 / 073238 (WO 03 / 073238), U.S. Patent Application Publication No. 2004 / 0214988 (US2 004 / 0214988A1), International Publication No. WO05 / 35727 A2), International Publication No. 05 / 74524 (WO05 / 74524A2), Chin, J. W.,et al.,Journal of the American Chemic al Society 124(2002)9026-9027, Chin, J.W. and Schultz, PG, ChemBioChem 11(2002)113 5-1137, Chin, JW, et al., PICAS United Sta. tes of America 99(2002)11020-11024, and W ang, L., and Schultz, PG, Chem. (2002) 1-10. all of which are incorporated herein by reference.

[0096] The term "Fc region-containing polypeptide" refers to a polypeptide that contains an Fc region, such as an antibody or refers to immunoadhesin (see below for definition).

[0097] The term "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Preferred FcRs are receptors that bind IgG antibodies (γ receptors), such as FcγRI and Fcγ Receptors of the RII and FcγRIII subclasses, including allelic variants and their The FcγRII receptor includes alternatively spliced ​​forms of the receptor. ("activating receptors") and FcγRIIB ("inhibitory receptors"). It has a similar amino acid sequence that differs in its cytoplasmic domain as activating receptor F. cγRIIA contains an immunoreceptor tyrosine-based activation motif in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreactive protein (ITAM) in its cytoplasmic domain. Contains receptor tyrosine-based inhibitory motifs (ITIMs) (Daeron, M, Annu. (See review in Rev. Immunol. 15 (1997) 203-234). FcR is Ravetch and Kinet, Annu.Rev.Immunol 9 (1991) 457-492, Capel, et al. 4 (1994) 25-34, and de Haas, et al., J. Lab. Cli n. Med. 126 (1995) 330-41. cRs, such as FcRs to be identified in the future, are encompassed by the term "FcR" in the present invention. The term is also used to refer to the neonatal receptor FcRn, which is responsible for transferring maternal IgG to the fetus. (Guyer, et al., J. Immunol. 117 (1976) 587 and and Kim, et al, J. Immunol. 24 (1994) 249).

[0098] As used herein, an "IgG Fc ligand" refers to a ligand that binds to the Fc region of an IgG antibody. Any biologically derived molecule, preferably a polypeptide, that forms an Fc / Fc ligand complex. Fc ligands include, but are not limited to, FcγR, Fc γR, FcγR, FcRn, C1q, C3, mannan-binding lectin, mannose receptor , Staphylococcal protein A, Streptococcal protein G and viral Fc ligands include the family of Fc receptors that are homologous to FcγR. Fc receptor homologs (FcRHs), which are the receptors for References: Unological Reviews 190(2002)123-136 The Fc ligands include as yet undiscovered molecules that bind Fc. Particular Fc ligands for IgG are FcRn and Fcγ receptors. As used herein, the term "Fc ligand" refers to a ligand that binds to the Fc region of an antibody to form an F / Fc ligand. The term refers to any biologically derived molecule, preferably a polypeptide, that forms a bond complex.

[0099] As used herein, "Fcγ receptor," "FcγR," or "Fc gamma R" refers to It binds to the Fc region of IgG antibodies and is a phagocytosis protein encoded by the FcγR gene. In humans, this family includes, but is not limited to, However, FcγRI (CD64), e.g., the isoforms FcγRIA, FcγR IB and FcγRIC, FcγRII (CD32), e.g., isoform FcγRI IA (including allotypes H131 and R131), FcγRIIB (FcγRIIB- 1 and FcγRIIB-2), and FcγRIIc, and FcγRIII ( CD16), e.g., isoform FcγRIIIA (allotypes VI58 and F15 8), and FcγRIIIb (including allotypes FcγRIIB-NA1 and Fcγ (including RIIB-NA2) (Jefferis, et al., Immunol Let t 82(2002)57-65, the entire contents of which are incorporated herein by reference), and any undiscovered human FcγR or FcγR isoform or allotype. FcγR includes, but is not limited to, human, mouse, rat, rabbit and The FcγR may be derived from any organism, including monkeys. The FcγR may be derived from a mouse, but is not limited thereto. However, FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) and FγRIII-2 (CD16-2) and any unidentified mouse FcγR or This includes FcγR isoforms or allotypes.

[0100] As used herein, "FcRn receptor" or "neonatal Fc receptor" refers to an IgG antibody that binds to the A protein that binds to the Fc region of the host and is encoded at least in part by the FcRn gene. FcRn refers to a protein that is expressed by, but is not limited to, human, mouse, rat, or rabbit. The polypeptide may be derived from any organism, including monkeys and monkeys. The FcRn protein comprises two polypeptides, often referred to as a heavy chain and a light chain. The light chain is β-2-microglobulin and the heavy chain is encoded by the FcRn gene. Unless otherwise specified herein, FcRn or FcRn protein refers to Fc It refers to the complex of Rn heavy chain and β-2-microglobulin.

[0101] As used herein, the term "IL-1RAcP-specific antibody" refers to an antibody specific for human IL-1RAcP. "IL-1RAcP specific antibody" refers to an antibody specific for VH The antibody has the specificity shown in FIG. 2 in relation to the VL and CDR sequences. Thus, for example, "the VH region is selected from the group consisting of the VH regions of SEQ ID NO: 1+n." and the VL region is selected from the group consisting of the VL regions of SEQ ID NO: 37+n, and n is a number from 0 to 3. An antibody selected from the group consisting of L-1RAcP-specific antibodies, comprising the VH region of SEQ ID NO: 1 and the VL region of SEQ ID NO: 37, the VH region of SEQ ID NO: 2 and the VL region of SEQ ID NO: 38 4 and the VL region of SEQ ID NO: 40, and an IL -1RAcP-specific antibody, comprising the VH region of SEQ ID NO: 3 and the VL region of SEQ ID NO: 39 The present invention refers to an antibody characterized by:

[0102] An "immunoconjugate" refers to a compound that is administered to a subject in need of treatment with one or more cytotoxic agents, such as chemotherapeutic agents, drugs, antiproliferative agents, thrombolytic agents, or other therapeutic agents. By "antibody" is meant an antibody conjugated to a cytochrome P450, another antibody or a radioisotope.

[0103] An "antibody fragment" refers to a portion of a full-length antibody, preferably the variable region or at least a portion thereof. Both contain an antigen-binding site. Examples of antibody fragments include diabodies, Fab fragments, and the like. scFv antibodies include, for example, those described by Huston, J.S. , Methods in Enzymol. 203 (1991) 46-88. There are.

[0104] As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to a "refers to a preparation of antibody molecules of a single amino acid composition. The term "chimeric antibody" refers to a preparation of antibody molecules of a single amino acid composition. The original variable regions, i.e., binding regions, and at least one constant region, derived from a different source or species, are It generally refers to monoclonal antibodies produced by recombinant DNA technology. According to the present invention, a chimeric antibody comprising a rabbit variable region and a human constant region and Humanized rabbit antibodies are particularly preferred. Other forms of antibodies have the class or subclass altered or changed from that of the original antibody. Such "chimeric" antibodies are also called "class-switched antibodies." Methods for producing the mAb include conventional recombinant DNA and immunohistochemical techniques currently well known in the art. and gene transfection techniques (see, e.g., Morrison, SL, et al,Proc.Natl.Acad.Sci.USA 81(1984)6851- 6855, U.S. Pat. No. 5,202,238 and U.S. Pat. (See US Pat. No. 5,204,244).

[0105] The term "humanized antibody" or "humanized form of an antibody" refers to an antibody in which the human variable regions are In a preferred embodiment, the VH and CDRs are The CDRs of the VL are grafted into the framework region of a human antibody to produce a "humanized antibody." " is produced (see, for example, Riechmann, L., et al., Nature 332 (1988) 323-327, and Neuberger, MS, et al., Na (See, e.g., J. Am. Soc. 314 (1985) 268-270). The work regions can be derived from the same or different human antibody sequences. The sequences may be those of naturally occurring human antibodies. The region is described, for example, in Lefranc, M.-P., Current Protocols in Immunology(2000) - Appendix IP A.1P.1 -A.1P.37, IMGT, the international ImMunoGeneTics information system (registered trademark) http: / / imgt.cines.fr) or http: / / vbase.mrc -Available via cpe.cam.ac.uk

[0106] Preferably, the present invention relates to a chimeric or humanized rabbit antibody having a variable light chain VL It is characterized by the inclusion of a serine instead of a cysteine ​​at amino acid positions 75-85 in The present invention relates to an antibody which

[0107] As used herein, the term "recombinant antibody" refers to an antibody of the present invention that is produced by recombinant means. All antibodies produced by This is intended to include antibodies produced in host cells, such as NS0 or CHO cells. Such recombinant human antibodies have variable and constant regions in a rearranged form. .

[0108] As used herein, the term "specifically binds to a target or an anti-target antibody" refers to a "To detect" refers to the binding of antibodies to their respective antigens (targets) by ELISA. In this regard, the ELISA preferably refers to the binding measured by binding each antigen to a solid The antibody is coated on a carrier and capable of forming an immune complex with the respective antigen or protein. and detecting the immune complex using a secondary antibody that binds to the antibody according to the present invention under conditions suitable for detection of the immune complex. and by measuring the optical density value (OD) using peroxidase-mediated color development. The term "antigen" according to the present invention refers to an antigen used for immunization. or a protein that contains said antigen as part of its protein sequence. For synthesis, a fragment of the extracellular domain of a protein (e.g., the first 20 amino acids) can be used. For detection / assay etc., the extracellular domain or the like of the protein can be used. Alternatively, the full-length protein can be used.

[0109] As used herein, the terms "specifically bind" or "specifically recognize" refer to an antibody that specifically binds to a target molecule. The antibody has a significant affinity for the antigen and preferably does not exhibit significant cross-reactivity. "Appreciable" binding affinity means that there is no 7 M -1 of, especially at least 10 8 M -1 of, more specifically, at least 10 9 M -1 of or still Even more specifically, at least 10 10 M -1 "Large binding affinity" "No cross-reactivity" antibodies are clearly visible to other undesirable proteins. The epitope-specific antibody according to the present invention is, for example, an antibody that does not bind to IL-1. It does not show significant cross-reactivity with other epitopes on RAcP. Such binding may be measured according to any means recognized in the art for measuring binding. In some embodiments, specific binding can be measured using competitive binding assays (e.g., EL It is measured by the International Standards Association (ISA).

[0110] As used herein, the term "inhibits IL-1RAcP-induced NFκB activity" refers to inhibiting NF-κB activity in luciferase reporter experiments. 293T / 17 [HEK 293 T / 17] (ATCC® CRL-11268™) cells were cultured using poly-D-lysine After stimulation with IL-1RAcP, the cell lysates were incubated with 100 mM NaCl and 100 mM NaCl. Steady-Glo® Luciferase Assay for Activated NF-κB The functional The supernatant containing the antibody binds to IL-1RAcP and inhibits NF-κB activation, which is low Signal is shown. Steady-Glo® Luciferase Assay Kit https: / / www.promega.de / resources / proto cols / technical-manuals / 0 / steady-glo-luci ferase-assay-system-protocol, and Alam, Ja nd Cook, JL (1990) Anal.Biochem.188,245-5 4, Wood, KV (1991) In: Bioluminescence and Chemiluminescence:Current Status,Stanle y, P., and Kricka, L., eds., John Wiley and S. ons, Chichester, NY, 543, Ow, DWet al. (1986 ).Science 234,856-9, De Wet, JRet al.(19 87) Mol. Cell. Biol. 7, 725-37, Wood, K. V. (1990 )PromegaNotes 28,1-3, Wood, KV (1991) In: Bioluminescence and Chemiluminescence: Cu rrent Status, Stanley, P. and Kricka, L., eds. .,John Wiley and Sons,Chichester,NY,11, In addition, U.S. Patent No. 5,283,179 (US5283179), U.S. Patent No. 5,641 641 (US5641641), U.S. Pat. No. 5,650,289 (US56 50289).

[0111] The antibody according to the invention comprises a VH region and a VL region or a portion thereof, which The two together are sufficient to specifically bind to their respective antigens.

[0112] All protein terms used herein refer to human proteins. This is stated explicitly when referring to proteins from a species.

[0113] As used herein, the term "IL-1RAcP" refers to a signal transduction pathway involved in IL-36 signal transduction. Human IL-1RAcP (U) is a co-receptor (by similarity) for IL1RL2, which is niProtKB Q9NPH3) in the IL-1 signal transduction pathway. The co-receptor for IL-1 associates with IL1R1 and binds IL1B, which mediates the induction of NF-κB. High-affinity interleukin that affects interleukin-1-dependent activation and other pathways The term "mouse IgG" as used herein forms a complex with the mouse IgG1 receptor (UniProtKB). "Mice IL-1RAcP" is mouse IL-1RAcP (UniProtKB Q61730 )

[0114] As used herein, the term "IL-1α" refers to human IL-1 (UniProtKB P As used herein, the term "IL-1β" refers to human IL-1β (U IL-1 regulates IL-2 release, B cell maturation and stimulates thymocyte proliferation by inducing fibroblast growth factor activity, as well as proliferation and proliferation of thymocytes. The IL-1 protein is involved in inflammatory responses and has been identified as an endogenous pyrogen ( UniProtKB).

[0115] As used herein, the term "IL-33" refers to human IL-33 (UniProtKB O95760), which binds to the IL1RL1 / ST2 receptor and transmits signals through it. This signal then propagates NF-κB and MAPK signaling in target cells. Refers to cytokines that activate signaling pathways.

[0116] As used herein, the term "IL-36" refers to human IL-36α (UniProtKB Q9UHA7), IL-36β (UniProtKB Q9NZH7) and / or IL-36γ (UniProtKB Q9NZH8) IL-36 is a 2 / IL-36R receptor and transmits signals through it, which in turn Activates NF-κB and MAPK signaling pathways in target cells to promote inflammation The IL-36 signaling pathway is a cytokine that leads to immune responses. Similar to the IL-1 system that shares IL1RAP, it is present in the epithelial barrier and is involved in local inflammatory responses. IL-36 acts on keratinocytes, dendritic cells, and T cells. Indirectly acts to promote skin inflammation by driving tissue invasion, cell maturation and cell proliferation It is thought to be involved in inflammation response (UniProtKB).

[0117] As used herein, the term "NFκB" refers to human nuclear factor NF-κB, which is From the 105 subunit (P19838) and p100 subunit (Q00653) "Inhibition of NFκB" refers, according to the present invention, to inhibition of NFκB-dependent luciferase in human cells. Such methods are described, for example, in the Windheit Institute of Technology, m M.et al.,Mol.Cell.Biol.28(2008)1783-17 91, Huang J. et al.PNAS USA 94(1997)12829- 12832, Xiaoxia L.et al.,Mol.Cell,Biol.19( 1999) 4643-4652. IL1β in 293T / 17 cells The method used according to the present invention for the inhibition of NFκB expression induced by NF-κB is described in the present patent application. Where mouse NFκB is meant, it is expressly intended herein to mean It is stated.

[0118] As used herein, the term "variable region (or domain) of an antibody according to the invention" (variable region (or domain) of the light chain) The variable region (VL) of the heavy chain (VH) is directly involved in binding of the antibody to the antigen. The variable light chain region and the variable heavy chain region are shown in FIG. Each region has the same general structure and is linked by three complementarity determining regions (CDRs). It contains four framework (FR) regions with extensive sequence conservation that are linked together. "Antigen-binding portion of an antibody," as used herein, refers to the portion of an antibody that is responsible for antigen binding. The antigen-binding portion of an antibody preferably comprises a "complementarity determining region" or "CD The CDR sequences are derived from Kabat, et al., Sequencing. nces of Proteins of Immunological Intere st,5th Ed.Public Health Service,National Institutes of Health, Bethesda, Md. (1991) Using this numbering system, a virtually linear amino acid sequence is , fewer amino acids corresponding to a shortening of or insertion into a FR or CDR of the variable region. or additional amino acids. For example, the heavy chain variable region may contain a single amino acid sequence after residue 52 of H2. may contain a single amino acid insertion (residue 52a according to Kabat) and heavy chain FR residue 82 Residues inserted after (e.g., residues 82a, 82b, and 82c by Kabat) The Kabat numbering of residues may be used to determine, for a given antibody, the sequence of the antibody and By alignment of regions of homology with standard Kabat numbered sequences The variable domain of the heavy chain of the antibody according to the present invention can be determined by the following method. It is composed of a purine domain and has a length of about 110 to 120 amino acids. The variable domain of an antibody's light chain consists of a single immunoglobulin domain and consists of approximately 1 It is between 10 and 120 amino acids in length.

[0119] In one embodiment, the antibody according to the invention comprises an Fc region or constant region derived from human origin. It includes a heavy chain portion and a light chain portion, and preferably includes all portions of the human constant region. As used herein, the term "Fc portion derived from human origin" refers to an Fc portion of the subclass IgG1, Fc portions of human antibodies of IgG2, IgG3 or IgG4, e.g., human IgG1 subclass Fc regions derived from human IgG1 subclasses, mutated Fc regions derived from human IgG1 subclasses (preferably L234A+ L235A mutation), Fc region derived from human IgG4 subclass or human IgG4 subclass-derived mutated Fc region (preferably with S228P mutation) In one embodiment, the antibody according to the invention comprises a human IgG1 subclass. Human constant chains are well known in the art and can be found, for example, in the Kabat ,EA (e.g. Johnson, G. and Wu, T.T., Nucleic A cids Res.28(2000)214-218).

[0120] In one embodiment, the antibody according to the invention is selected from the group of VH sequences according to the invention. For the amino acid sequence, at least 90%, 91%, 92%>, 93%>, 94%, Heavy chain variable regions having 5%, 96%, 97%, 98%, 99% or 100% sequence identity In certain embodiments, the nucleotide sequence comprises at least 90%, 91%, 92% , 93%, 94%, 95%, 96%, 97%, 98% or 99% identity The sequence may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence. Thus, the antibodies retain the ability to specifically bind to their respective antigens according to the present invention. In certain embodiments, a total of 1 to 10 amino acids are present in each of said VH sequences. In certain embodiments, the substitution, insertion and / or deletion is The insertions or deletions are in regions outside the CDRs (ie, in the FRs).

[0121] In one embodiment, the antibody according to the invention comprises a VL sequence according to the invention At least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, 99% or 100% sequence identity to a light chain variable region (VL), where n is a number from 0 to 5. In certain embodiments, at least 90% 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical The VL sequence may have substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence. whereby the antibodies retain the ability to specifically bind to their respective antigens. In certain embodiments, a total of 1 to 10 amino acids are In certain embodiments, substitutions, insertions or deletions have been made. The deletion is in a region outside the CDR (i.e., in the FR). These include affinity matured antibodies, which can be produced by methods known in the art. et al.Bio / Technology 10:779-783(1992) Affinity maturation by H and V domain shuffling is described. Alternatively, random mutagenesis of framework residues was performed as described by Barbas et al., Proc. c Nat. Acad. Sci, USA 91:3809-3813(1994), Sc Hier et al., Gene 169:147-155 (1995), Yelto n et al., J.Immunol.1 55:1994-2004(1995), Jackson et al., J. Immunol. 1 54(7):3310-9( 1995), and Hawkins et al., J. Mol. Biol. 226:8 89-896 (1992) and International Publication No. WO2010108127 (WO20101 08127) for peptide or polypeptide sequences. "Percent (%) Amino Acid Sequence Identity" is calculated by aligning sequences and introducing gaps. If necessary, conservative substitutions are made to the sequence after the maximum percent sequence identity has been achieved. The amino acids in a particular peptide or polypeptide sequence are not considered to be part of the identity of the It is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the candidate sequence. Alignment to determine amino acid sequence identity of a single molecule is known in the art. In various ways that are within the skill of the art, such as publicly available computer software, e.g. For example, BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR ) software can be used to achieve this.

[0122] The antibodies according to the invention are preferably produced by recombinant means. , which are well known in the art and which are incorporated herein by reference, are incorporated herein by reference in their entirety. Subsequently, the antibody polypeptide is isolated and typically purified to a pharma- ceutical acceptable degree of purity. For protein expression, the light chain of the antibody or fragment thereof according to the invention is and the nucleic acid encoding the heavy chain is inserted into an expression vector by standard methods. The host cells may be any suitable prokaryotic or eukaryotic host cell, such as CHO cells, NSO cells, SP 2 / 0 cells, HEK293 cells, COS cells, yeast or E. coli cells, The antibody is then recovered from the cells (either from the supernatant or after cell lysis). The structures are well known in the art and are described, for example, in Makrides, SC, Pro tein Expr.Purif.17(1999)183-202, Geisse,S. .,et al,Protein Expr.Purif.8(1996)271-28 2, Kaufman, RJ, Mol.Biotechnol.16(2000)15 1-161, Werner, RG, Drug Res. 48 (1998) 870-8 The antibodies have been described in 80 review articles. The present invention may be in purified, partially purified or pure form. Components or other contaminants, such as other cellular nucleic acids or proteins, are removed by standard techniques. By techniques such as column chromatography and other techniques well known in the art. Current Protocols in Biotechnology (Ausubel, F., et al., ed.) s in Molecular Biology,Greene Publishing and Wiley Interscience, New York (1987). Expression in NSO cells is determined by, for example, the method described in Barnes et al. ,LM,et al,Cytotechnology 32(2000)109-1 23, Barnes,LM,et al,Biotech.Bioeng.73(2 001) 261-270. Transient expression is described, for example, in Durocher, Described by Y., et al., Nucl. Acids. Res. 30 (2002) E9 The cloning of the variable domains is carried out as described by Orlandi, R., et al., Proc. .Natl.Acad.Sci.USA 86(1989)3833-3837, Car ter,P.,et al,Proc.Natl.Acad.Sci.USA 89(1 992)4285-4289, Norderhaug, L., et al, J. Immu Nol. Methods 204 (1997) 77-87. The transient expression system (HEK 293) was kindly provided by Schlaeger, E.-J. and Chris Tensen, K. Cytotechnology 30(1999)71-8 3 and by Schlaeger, E.-J. in J. Immunol. .Methods 194 (1996) 191-199. Clonal antibodies can be purified by conventional immunoglobulin purification procedures, e.g., protein A-Sepharose, hydrochloride, Culture media was analyzed by hydroxyl apatite chromatography or affinity chromatography. It is appropriately separated from the ground.

[0123] DNA and RNA encoding the monoclonal antibodies are sequenced using conventional procedures. It is preferable to use RT PCR.

[0124] The antibody obtained from the cell line is a preferred embodiment of the present invention. Mutations can be made by introducing nucleotide changes into the DNA encoding the antibody or by They are produced by peptide synthesis. They are not involved in maintaining the proper conformation of the antibody. All cysteine ​​residues are substituted to improve the oxidative stability of the molecule and reduce aberrant cross-linking. Generally, one or more cysteine ​​bonds may be replaced with serine. may be added to the antibody to improve the quality of the antibody (especially if the antibody is an Fv fragment, (If it is a fragment).

[0125] The heavy chain variable region and the light chain variable region of the present invention each include a promoter, a translation initiation region, a constant region, and a region, 3' untranslated region, polyadenylation and transcription termination sequences. The heavy and light chain expression constructs are assembled in a single vector to form an expression vector construct. are combined and co-transfected into a host cell, or sequentially transfected or transfected separately and then fused to express both chains. A single host cell may be formed.

[0126] One aspect of the invention is a pharmaceutical composition comprising an antibody according to the invention. A further embodiment of the present invention is the use of an antibody according to the present invention for the manufacture of a pharmaceutical composition. An embodiment is a method for producing a pharmaceutical composition comprising an antibody according to the invention. The present invention also provides compositions, e.g., compositions containing an antibody according to the invention, formulated together with a pharmaceutical carrier. For example, pharmaceutical compositions are provided.

[0127] Furthermore, the antibodies according to the invention are useful in the treatment of diseases in which dysregulation of the target is the underlying cause. One aspect of the present invention is a pharmaceutical composition for the treatment of cancer.

[0128] Another aspect of the invention is an antibody according to the invention for the treatment of cancer. The antibodies according to the invention have been shown to be effective in mouse tumor models, e.g. ;Begley DA;Sundberg JP;Bult CJ;Eppig JT, The Mouse Tumor Biology database.,Nat Re v Cancer 2008 Jun;8(6):459-65. Thus, one aspect of the present invention is a pharmaceutical composition for the treatment of cancer.

[0129] Another aspect of the invention is an antibody according to the invention for the treatment of cancer.

[0130] Another aspect of the invention relates to the use of an antibody according to the invention for the manufacture of a medicament for the treatment of cancer. The use of.

[0131] Another aspect of the invention is a method for treating a patient suffering from cancer, comprising administering an antibody according to the invention to said patient. The therapeutic method is carried out by administering the above-mentioned compound to a patient in need of such treatment.

[0132] As used herein, a "pharmaceutical carrier" includes any and all physiologically compatible Solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. Preferably, the carrier is administered intravenously, intramuscularly, subcutaneously, parenterally, or via spinal injection. The pharmaceutical composition is suitable for intradermal or epidermal administration (eg by injection or infusion).

[0133] A composition of the present invention can be administered by a variety of methods known in the art. As will be apparent to one of skill in the art, the route and / or mode of administration will vary depending on the desired outcome. In order to administer the compounds of the invention by a particular route of administration, the compounds is coated with a material that inhibits its inactivation or the compound is co-inoculated with said material. For example, the compound may need to be administered to a subject in an appropriate carrier, e.g. The drug may be administered in a pharmacopoeia or diluent. Pharmaceutically acceptable diluents include physiologically acceptable diluents. Saline and aqueous buffer solutions are included. Pharmaceutical carriers include sterile aqueous solutions or dispersions. as well as sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutical agents is well known in the art.

[0134] As used herein, the terms "parenteral administration" and "administered parenterally" refer to enteral and and administration methods other than topical administration, usually by injection, The injection may be by any of the following means: intravenous, intramuscular, intraarterial, intramedullary, intracapsular, intraorbital, intracardiac, Intradermal, intraperitoneal, intratracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intrathecal, epidural and These include intrasternal injections and infusions.

[0135] The term "cancer" as used herein includes, for example, lung cancer, non-small cell lung (NSCL) cancer, pulmonary cancer, and pulmonary sarcoma. Bronchiectasis of the lung, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, blackheads of the skin or eye Melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, Carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, malignant tumors of the vulva, Hodgkin's disease, Esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue cancer urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis carcinoma, mesothelioma, hepatocellular carcinoma, cholangiocarcinoma, tumors of the central nervous system (CNS), spinal cord cancer, brain stem glioma , glioblastoma multiforme, astrocytoma, schwannoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma, pituitary gland adenoma, lymphoma, lymphocytic leukemia, e.g., refractory forms of any of the above cancers, or It may be one or more of a combination. Preferably, such cancer is breast cancer, colon cancer, lung cancer. Or pancreatic cancer.

[0136] These compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the presence of microorganisms can be achieved by the sterilization procedures described above and the use of various antibacterial and antifungal agents, e.g. Both are protected by the inclusion of parabens, chlorobutanol, phenol, sorbic acid, etc. It is also possible to prove that the composition contains isotonic agents such as sugars, sodium chloride, etc. In addition, it may be desirable to prolong absorption of the injectable pharmaceutical form by delaying absorption. The inclusion of agents that induce stimuli, such as aluminum monostearate and gelatin, Regardless of the route of administration chosen, it should be used in a suitable hydrated form. The compounds of the present invention and / or the pharmaceutical compositions of the present invention can be synthesized by conventional methods known to those skilled in the art. The active ingredient in the pharmaceutical composition of the present invention is formulated into a pharma- ceutical acceptable dosage form by The actual dose level will depend on the desired therapeutic response for a particular patient, composition, and mode of administration. The dosage may be varied to obtain an amount of active ingredient that is effective to achieve the desired goal but is not toxic to the patient. The dose level selected will depend on various pharmacokinetic factors, including the dosage of the present invention being used. The activity of the particular composition, the route of administration, the time of administration, the excretion rate of the particular compound used, The duration, other drugs, compounds and / or substances used in combination with the particular composition used or the material, age, sex, weight, condition, general health history and past medical history of the patient to be treated. It will depend on medical history and similar factors well known in the medical arts.

[0137] The method according to the present invention can be summarized as comprising the steps of immunization, B cell isolation, and B cell cloning. A step of enrichment for B cells, a step of isolation of single B cells, preferably co-cultivation with feeder cells, The steps of culturing, selecting single B cells containing the respective mRNAs, and Such a method includes, for the production of monospecific antibodies, For example, International Publication No. WO2011147903 and International Publication No. No. 007003041 (WO2007003041), International Publication No. 2008045140 No. (WO2008045140), International Publication No. 2004106377 (WO20041 06377), European Patent Application Publication No. 1255780 (EP1255780) and and European Patent Application Publication No. 1633787 (EP1633787) .

[0138] immunization Immunization can be carried out according to methods known from the prior art, for example with a target antigen or a fragment thereof, This can be achieved by using the complete protein antigen or its fragments, or the DNA of antigen-expressing cells. Preferably, the IL-1RAcP antigen is a combination of said antigen and human Fc polypeptide. Preferably, the immunization step in step i) is a fusion polypeptide consisting of a polypeptide. is repeated at least three times, and optionally up to six times, within a 90 day period. (e.g., if already identified after the fourth immunization, no further immunization is necessary). Or complete Freund's adjuvant (CFA) or CFA and incomplete Freund's adjuvant Adjuvant (IFA) is used as an adjuvant.

[0139] Isolation of B cells B cells are isolated from rabbits, preferably from rabbit blood. B cells are isolated from rabbits for a third time or After the sixth immunization, the mouse is isolated by the eighth day, preferably between the fifth and seventh days. Alternatively, PBMCs can be isolated and depleted of macrophages (see, e.g., European Patent No. 048847 0 (see EP0488470) and used as B cells. Isolation can also involve, for example, binding non-B cells to non-B cell markers, such as anti-CD2 antibodies, anti-CD14 antibodies, , labeled with anti-CD16, anti-CD36, anti-CD43 and anti-CD235a antibodies and separating the labeled non-B cells from the unlabeled B cells. It is also possible.

[0140] B cell enrichment Antibody producing and antigen-specific B cells are preferably used for immunization. Isolation by treatment with IL-1RAcP antigen or cells expressing the respective antigen Preferably, the antigen and the cells expressing the antigen are enriched in an immobilized form. Therefore, antigen-specific B cells can be easily isolated. The method is described, for example, in Kodituwakko AP et al., Immunol. Cell. Biol. (2003) 81, 163-170 and European Patent No. 0488470 This is described in the specification (EP0488470).

[0141] Isolation of single B cells Isolation of rabbit single B cells is preferably performed by FACS. For CS selection, anti-rabbit IgG is used. Such selected single B cells are These are antibody-producing B cells.

[0142] Co-culture with feeder cells Preferably, the antigen-producing B cells are cultured on feeder cells before the selection step (see below) is performed. Such feeder cells are preferably thymoma cell lines, e.g. For example, the murine EL4 thymoma cell line, preferably a mutagenized cell line; Preferably, the thymoma cell line is mutagenized to a bromodeoxyuridine resistant mutant. (For example, EL4-B5 cells, Wen L. et al., Eur. J. Immuno 17(1987)887-92). This increases the amount of antibody in the cell supernatant (e.g. Zubler, RH, et al., Eur. J. Immunol. 14 (1984 )357-63, Wen L.et al.,Eur.J.Immunol.17(19 87)887-92, Hoffmann P et al., J Immunol.Me thods 1996;196(1):85-91, Roy A. et al., JH ematother.Stem Cell Res.2001;10(6):873-8 0, Dlu A.et al.,Proc.Nati.Acad.Sci.USA Vo 84, pp. 9140-9144, 1987, and European Patent No. 0488470 (see EP0488470)), and analysis and selection of the secreted rabbit antibodies. Make it easier.

[0143] Selection of single B cells containing mRNA A polypeptide encoding the heavy and light chain variable regions of the antibody according to the present invention Selection of single B cells containing mRNA is preferably performed after co-culturing with feeder cells. Secreted rabbit antibody that specifically binds to the IL-1RAcP antigen used for immunization The analysis can be carried out by analyzing the cell supernatant for E. Immunoglobulin sequences were then analyzed by LISA. From, for example, de Wildt RM, Hoet RM. Methods Mol. ol.2002;178:121-31 and then analyzed by, for example, RT PCR. This can be analyzed.

[0144] The production of antibodies according to the invention expressed by single B cells is carried out by recombinant means. It is possible.

[0145] The techniques and procedures described or referenced herein may be implemented in accordance with, for example, Sambrook et al.,Molecular Cloning: A Laboratory M annual 3rd.edition(2001)Cold Spring Harbo r Laboratory Press, Cold Spring Harbor, N. Y.CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FMAusubel,et al.eds.,(2003));the seri es METHODS IN ENZYMOLOGY(Academic Press, Inc.): PCR 2:A PRACTICAL APPROACH(MJMac Pherson, BD Hames and GRTaylor eds.(19 95)), Harlow and Lane, eds. (1988) ANTIBODIE S,A LABORATORY MANUAL,and ANIMAL CELL CU The widely used method is described in LTURE (RI Freshney, ed. (1987)). This is a way to do it.

[0146] According to the present invention, suitable CHO cells or cell lines derived from Chinese hamster ovary tissue are , a cell line established from the ovarian tissue of the Chinese hamster (Crimson vulgaris). For example, the Journal of Experimental Medicine,108,945(1958), Proc.Nat Acad.Sc i.USA,60,1275(1968), Genetics,55,513(1968 ), Chromosoma, 41, 129 (1973), Methods in Cel l Science,18,115(1996), Radiation Research h,148,260(1997), Proc.Nat Acad.Sci.USA,77 ,4216(1980), Proc.Nat Acad.Sci.,60,1275(1 968), Cell, 6, 121 (1975), Molecular Cell Gen Etics, Appendix I, II (pp.883-900) and other publications. In addition, the ATCC (American Type Culture Collection) CHO-K1 (ATCC CCL-61), DUXB1 1 (ATCC CCL-9096) and Pro-5 (ATCC CCL-1781) and CHO- S (Life Technologies, Catalog No. 11619) or the cell line. The sub-cell lines obtained by adapting using various media were used in the present invention. You may do so.

[0147] Specific embodiments of the present invention are listed below.

[0148] The present invention relates to a monoclonal antibody that specifically binds to human IL-1RAcP.

[0149] The monoclonal antibody preferably further binds to mouse IL-1RAcP. It is characterized by:

[0150] The monoclonal antibody more preferably inhibits IL-1RAcP-induced NFκB. It is characterized by inhibiting B activity.

[0151] More preferably, the monoclonal antibody is directed against mouse IL-1RAcP. It is characterized by further inhibiting mouse NFκB activity.

[0152] The monoclonal antibody is more preferably an antibody against IL-1α, IL-1β, IL-33 and / or inhibits IL-36-stimulated NFκB activity.

[0153] The antibody is characterized in that it inhibits IL-1α-stimulated NFκB activity.

[0154] The antibody is further characterized in that it inhibits IL-1β-stimulated NFκB activity. .

[0155] The antibody is also characterized in that it inhibits IL-33-stimulated NFκB activity.

[0156] The antibody is further characterized in that it inhibits IL-36-stimulated NFκB activity. .

[0157] The antibodies are IL-1β / IL-1R1 / IL-1RAcP, IL-1α / IL-1R 1 / IL-1RAcP, IL-33 / ST2 / IL-1RAcP and IL-36 / IL NFκ stimulated by a complex selected from the group consisting of IL-36R / IL-1RAcP It is characterized by inhibiting B activity.

[0158] The antibody was administered at a concentration of 5 μg / ml (rabbit IgG isotype, molecular weight 150 KD). 0.5 μg / ml of human IL-1α, IL-1β, IL-33 and / or or IL-36 (for molecular weight, see UniProtKB / Swiss-Prot) Lysates of 293T / 17 cells stimulated with NFκB activity was measured using the present invention in a 5'-guinea pig ATCC® CRL-11268™ strain. 70% or more, preferably 80% or more, relative to a similar assay without the antibody The inhibitory effect is characterized by inhibiting the activity of the enzyme by preferably 90% or more, and more preferably 95% or more.

[0159] Preferably, the antibody is at a concentration of 5 μg / ml and is 0.5 μg / ml of murine IL-1 α, IL-1β, IL-33 and / or IL-36 (molecular weights are listed in the UniProtKB / Swiss-Prot) in lysates of each mouse cell line stimulated with NFκB activity was increased by 70% compared to a similar assay without the antibody according to the invention. or more, preferably 80% or more, preferably 90% or more, more preferably 95% or more. The present invention is characterized by the above.

[0160] The antibodies are directed against IL-1α, IL-1β, IL-33 and / or IL-36, respectively. Luciferase activity stimulated by NF-κB was measured in 293T / 17 cells (NF-κB reporter gene expression vector). 293T / 17-FR cells transfected with luciferase under control of Inhibits in.

[0161] The antibody may also be induced by an antibody according to the present invention that contains the Fc region of wild-type human IgG. The antibody is characterized in that it exhibits an ADCC that is reduced by at least 20% of the ADCC observed in the control antibody.

[0162] Preferably, the antibody has a higher affinity than an antibody according to the invention that comprises a wild-type IgG Fc region. and human FcγRIIIA and / or FcγRIIA and / or FcγRIIA. γRI, wherein the ADC induced by said antibody according to the invention C is an ADC induced by an antibody according to the invention comprising the Fc region of wild-type human IgG. C is reduced by at least 20%.

[0163] The antibody comprises L234A and L235A of the Fc region of human IgG1 or human IgG It is particularly notable that the antibody contains at least the amino acid substitutions S228P and L235E in the Fc region of antibody No. 4. It is a sign.

[0164] The antibody further comprises a heavy chain variable (VH) region selected from the group consisting of the VH regions of SEQ ID NO: 1 to SEQ ID NO: 77. and wherein the VH region is at least 90% identical to a VH region selected from the group consisting of: do.

[0165] The antibody preferably has a light chain variable (VL) region represented by any one of SEQ ID NOs: 78 to 154. VL domains selected from the group consisting of It is characterized by:

[0166] The antibody also preferably has a VH region which is at least identical to the VH region of SEQ ID NO: 1+n. 90% identical, and the VL region is at least 90% identical to the VL region of SEQ ID NO: 78+n. wherein n is a number selected from the group consisting of 0 to 76. do.

[0167] The antibody according to the present invention, wherein the antibody is selected from the group consisting of SEQ ID NO: 214, SEQ ID NO: 216, SEQ ID NO: 2 19, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:228, SEQ ID NO:156, SEQ ID NO:1 59, SEQ ID NO:183, SEQ ID NO:164, SEQ ID NO:163, SEQ ID NO:161, SEQ ID NO:1 57, SEQ ID NO:155, SEQ ID NO:174, SEQ ID NO:166, SEQ ID NO:173, SEQ ID NO:1 77, SEQ ID NO: 158, SEQ ID NO: 291, SEQ ID NO: 2 93, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:305, SEQ ID NO:2 33, SEQ ID NO:236, SEQ ID NO:260, SEQ ID NO:241, SEQ ID NO:240, SEQ ID NO:2 38, SEQ ID NO:234, SEQ ID NO:232, SEQ ID NO:251, SEQ ID NO:243, SEQ ID NO:2 50, SEQ ID NO: 254, SEQ ID NO: 235 and SEQ ID NO: No. 368, SEQ ID NO: 370, SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: No. 382, ​​SEQ ID NO: 310, SEQ ID NO: 313, SEQ ID NO: 337, SEQ ID NO: 318, SEQ ID NO: No. 317, SEQ ID NO: 315, SEQ ID NO: 311, SEQ ID NO: 309, SEQ ID NO: 328, SEQ ID NO: CDRs selected from the group consisting of SEQ ID NO:320, SEQ ID NO:327, SEQ ID NO:331, SEQ ID NO:312 Antibodies characterised in that they comprise a VH region comprising each of the H3 sequences are preferred.

[0168] Also, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 452, SEQ ID NO:459, SEQ ID NO:387, SEQ ID NO:390, SEQ ID NO:414, SEQ ID NO: 395, SEQ ID NO:394, SEQ ID NO:392, SEQ ID NO:388, SEQ ID NO:386, SEQ ID NO: 405, SEQ ID NO: 397, SEQ ID NO: 404, SEQ ID NO: 408, SEQ ID NO: 389 Selected light chain CDRL1 sequences are SEQ ID NO:522, SEQ ID NO:524, SEQ ID NO:527, No. 528, SEQ ID NO: 529, SEQ ID NO: 536, SEQ ID NO: 464, SEQ ID NO: 467, SEQ ID NO: No. 491, SEQ ID NO: 472, SEQ ID NO: 471, SEQ ID NO: 469, SEQ ID NO: 465, SEQ ID NO: No. 463, SEQ ID NO: 482, SEQ ID NO: 474, SEQ ID NO: 481, SEQ ID NO: 485, SEQ ID NO: CDRL2 sequences selected from the group of SEQ ID NO: 466, SEQ ID NO: 599, SEQ ID NO: 601 , SEQ ID NO:604, SEQ ID NO:605, SEQ ID NO:606, SEQ ID NO:613, SEQ ID NO:541 , SEQ ID NO:544, SEQ ID NO:568, SEQ ID NO:549, SEQ ID NO:548, SEQ ID NO:546 , SEQ ID NO:542, SEQ ID NO:540, SEQ ID NO:559, SEQ ID NO:551, SEQ ID NO:558 , SEQ ID NO: 562, and SEQ ID NO: 543. Also preferred is an antibody characterized in that it comprises a VL region.

[0169] In a further embodiment, the antibody comprises a VH region selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:2. 77 VH regions.

[0170] The antibody further comprises a VL region consisting of the VL regions of SEQ ID NO: 78 to SEQ ID NO: 154. The compound is characterized in that it is selected from the group consisting of:

[0171] The VH region is SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67 , SEQ ID NO:74, SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:29, SEQ ID NO:10, SEQ ID NO:9, SEQ ID NO:7, SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:20, SEQ ID NO:12, SEQ ID NO:19, The antibody is characterized in that it is selected from the group consisting of the VH region of SEQ ID NO: 23 and SEQ ID NO: 4. More preferred.

[0172] Preferably, the heavy chain variable region (VH) sequence is SEQ ID NO: 60, or SEQ ID NO: 62, or or SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:74, SEQ ID NO:2, SEQ ID NO: 5, SEQ ID NO:29, SEQ ID NO:10, SEQ ID NO:9, SEQ ID NO:7, SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:20, SEQ ID NO:12, SEQ ID NO:19, SEQ ID NO:23, or SEQ ID NO:4 .

[0173] The VL region is represented by SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 143, No. 144, SEQ ID NO: 151, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 106, SEQ ID NO: 87, SEQ ID NO:86, SEQ ID NO:84, SEQ ID NO:80, SEQ ID NO:78, SEQ ID NO:97, SEQ ID NO: Selected from the group consisting of the VL regions of SEQ ID NO: 89, SEQ ID NO: 96, SEQ ID NO: 100, and SEQ ID NO: 81 Further preferred is an antibody characterized in that

[0174] Preferably, the light chain variable region (VL) sequence is SEQ ID NO: 137, or SEQ ID NO: 139. , or SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 151, SEQ ID NO: 79, SEQ ID NO:82, SEQ ID NO:106, SEQ ID NO:87, SEQ ID NO:86, SEQ ID NO:84, Row number 80, sequence number 78, sequence number 97, sequence number 89, sequence number 96, sequence number 10 0, or sequence number 81.

[0175] The VH region is SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: No. 67, SEQ ID NO: 74, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 29, SEQ ID NO: 10, SEQ ID NO: No. 9, SEQ ID NO: 7, SEQ ID NO: 3, SEQ ID NO: 1, SEQ ID NO: 20, SEQ ID NO: 12, SEQ ID NO: 1 9, SEQ ID NO: 23, and SEQ ID NO: 4, and the VL region thereof is selected from the group consisting of SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 151, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 106, SEQ ID NO: 87, SEQ ID NO: SEQ ID NO: 86, SEQ ID NO: 84, SEQ ID NO: 80, SEQ ID NO: 78, SEQ ID NO: 97, SEQ ID NO: 89, 96, SEQ ID NO: 100, and SEQ ID NO: 81. Characterized antibodies are most preferred.

[0176] In one embodiment, the antibody according to the invention comprises the sequence of SEQ ID NO: 137 and SEQ ID NO: 60 or The antibodies according to the invention also include SEQ ID NO: 142 and SEQ ID NO: 65, or SEQ ID NO: 143 and SEQ ID NO: 66, or SEQ ID NO: 144 and SEQ ID NO:67, SEQ ID NO:151 and SEQ ID NO:74, or SEQ ID NO:79 and SEQ ID NO: Column number 2, or SEQ ID NO:82 and SEQ ID NO:5, or SEQ ID NO:106 and SEQ ID NO: 29, or SEQ ID NO: 87 and SEQ ID NO: 10, or SEQ ID NO: 86 and SEQ ID NO: 9, Or SEQ ID NO: 84 and SEQ ID NO: 7, or SEQ ID NO: 80 and SEQ ID NO: 3, or 78 and SEQ ID NO: 1. Alternatively, the antibody according to the invention may comprise SEQ ID NO: 97 and and SEQ ID NO:20, or SEQ ID NO:89 and SEQ ID NO:12, or SEQ ID NO:96 and SEQ ID NO: 19, or SEQ ID NO: 100 and SEQ ID NO: 23, or SEQ ID NO: 81 and SEQ ID NO: Includes column number 4.

[0177] SEQ ID NO: 79 and SEQ ID NO: 2, or SEQ ID NO: 81 and SEQ ID NO: 4, or SEQ ID NO: No. 139 and SEQ ID NO: 62, or SEQ ID NO: 80 and SEQ ID NO: 3, or SEQ ID NO: 7 Particularly preferred is an antibody according to the invention comprising SEQ ID NO: 8 and SEQ ID NO: 1.

[0178] The antibody preferably has a VH region selected from the group consisting of VH regions of SEQ ID NO: 1+n. and wherein the VL region is selected from the group consisting of the VL regions of SEQ ID NO: 78+n, In this case, n is a number selected from the group consisting of 0 to 76.

[0179] In a further embodiment, the antibody comprises the CDR of SEQ ID NO: 155+n. 1H region, CDR2H region of SEQ ID NO: 232+n, and CDR3 of SEQ ID NO: 309+n H region, wherein n is from 0 to 76 The number is selected from the group consisting of:

[0180] The antibody preferably comprises the CDR1L region of SEQ ID NO: 386+n, the CDR1L region of SEQ ID NO: 463+n and a VL region comprising a CDR3L region of SEQ ID NO:540+n wherein n is selected from the group consisting of 0 to 76. It is characterized in that the number is

[0181] The antibody preferably comprises a CDR1H region of SEQ ID NO: 155+n, a CDR1H region of SEQ ID NO: A VH region comprising a CDR2H region of SEQ ID NO: 232+n and a CDR3H region of SEQ ID NO: 309+n. and the antibody comprises a VH region selected from the group consisting of CDR1 of SEQ ID NO: 386+n. L region, CDR2L region of SEQ ID NO: 463+n, and CDR3L region of SEQ ID NO: 540+n The VL domain is selected from the group of VL domains comprising the VL domain, wherein n is 0 to 76. The number is selected from the group consisting of:

[0182] The antibody may comprise a CDR sequence similar to that of an antibody selected from the group consisting of the antibodies listed in FIG. It is particularly notable that the antibody comprises a VH region and a VL region, each of which includes a CDR1 region, a CDR2 region and a CDR3 region. It can be a sign.

[0183] Preferably, the antibody is the antibody P013.S.01.B.B03, P013.S.01 .B.A05, P013.S.01.B.C04, P013.S.01.B.H01, P 013.S.01.B.D03, P013.S.01.B.E02, P013.S.02 .B.A04, P013.S.02.B.A05, P013.S.02.B.A02, P 013.S.02.B.D03, P013.S.02.B.H01, P013.S.02 .B.F01, P013.S.02.B.B04, P013.S.02.B.C02, P 013.S.02.B.B05, ​​P013.S.02.B.A03, P013.S.02 and P013.S.02.B.H03 ​​and P013.S.02.B.G05. The same epitope is bound to IL-1RAcP, which inhibits NFκB activity induced by IL-1RAcP. It is characterized by:

[0184] In one embodiment, the antibody is a rabbit / human chimeric antibody or a humanized antibody. It is characterized by the above.

[0185] The present invention also relates to a method for the prevention of NFκB activity stimulated by IL1β according to the present invention. A method for producing a monoclonal rabbit antibody against human IL-1RAcP, comprising: i) a number of samples obtained from the rabbits after immunization with IL-1RAcP Isolating antibody-producing single cells; ii) measuring binding to IL-1RAcP in the supernatants of the single cells separately; Top, iii) the supernatant exhibits binding to human and mouse IL-1RAcP and NFκB activity stimulated by IL-1β, IL-33 and / or IL-36 selecting a single cell if iv) isolating antibodies having the characteristics of step iii) from the selected cells. Top The present invention relates to a manufacturing method thereof.

[0186] Preferably, the method comprises the step of: culturing rabbit antibody-producing single cells comprising a rabbit hybridoma single B cell line; It is characterized by being a cell.

[0187] The method also includes determining whether the rabbit is a candidate for human IL-1RAcP after immunization with the antigen. Binding and stimulation by IL-1α, IL-1β, IL-33 and / or IL-36 If inhibition of NFκB activity is found, antibody-producing single cells are isolated from the animal. or isolating rabbit hybridoma cells obtained from said rabbit. do.

[0188] The present invention relates to the use of said antibody for the manufacture of a pharmaceutical composition.

[0189] The present invention relates to a supernatant of a single rabbit cell producing an antibody that binds to human IL-1RAcP. and stimulated by IL-1α, IL-1β, IL-33 and / or IL-36 The present invention relates to a supernatant which inhibits NFκB activity.

[0190] The present invention provides a method for treating an IL-1 mediated disease in a patient, comprising administering to the patient a pharma- tically effective amount of The present invention relates to a method of treatment comprising administering the antibody.

[0191] The present invention relates to a method for the treatment of a disease caused by the administration of an antibody according to any one of the embodiments, comprising administering to a patient a therapeutically effective amount of the antibody, comprising administering to said patient a therapeutically effective amount of the antibody according to any one of the embodiments, and and an effective amount of

[0192] The invention also provides a method of treating an IL-1 mediated disorder in a patient, comprising administering to the patient a therapeutic agent of the invention. The present invention relates to a method of treatment comprising administering the pharmaceutical composition.

[0193] Working Example Example 1: Compounds [Table 1]

[0194] Example 2: Immunization of rabbits Rabbits were repeatedly immunized with hu-IL-1RAcP-Fc. The blood of these animals The B lymphocytes were isolated from the collected blood. Single B cells were then placed in a well of a microtiter plate. These B cell pretreated supernatants were sorted and expanded into hu- IL-1RAcP ELISA was performed. 409 monoclonal antibodies (= total Of all supernatants tested, 4.7%) were identified as binding to hu-IL-1RAcP. 23 monoclonal antibodies also bound to mouse IL-1RAcP and inhibited IL1β-induced It was found to inhibit human or mouse NF-κB activity.

[0195] a) Immunization of rabbits (Scheme 1) Human IL-1RAcP (IL-1R) fused to recombinant human Fc chimeric protein Two different immunization schemes, i.e., Scheme 1: Scheme 1 and Scheme 2 were investigated. Three New Zealand tiger reptiles were used for immunization with Scheme 1. New Zealand White (NZW) rabbits were given 1 ml of the immunogen on days 0 and 7. The mice were immunized by injection on days 14, 28, 42 and 56. Proteins were diluted in PBS, pooled in equimolar amounts, and resuspended in complete Freund's buffer prior to use. The immunogen was mixed 1:1 (volume / volume) with adjuvant (CFA). The final concentration of immunogen was 400 μg. The same dose was used per animal for the first immunization, and for the second, third, fourth, fifth and For the first and sixth immunizations, 200 μg of immunogen was used per animal. , in EDTA-covered tubes after the third, fourth, fifth and sixth immunizations. The mice were harvested 5, 6 and 7 days after immunization. The antibodies according to the present invention were isolated from blood samples taken after the third immunization. The antibodies were isolated from blood samples taken after the 4th, 5th and 6th immunizations.

[0196] b) Immunization of rabbits (Scheme 2) For immunization according to scheme 2, six NZW rabbits were each immunized with 1 ml of immunization solution. Subcutaneous injection on days 0, 7, 14, 28, 42, 56, and 70 For the first injection, the protein was diluted in PBS and Molar amounts were pooled and mixed 1:1 (volume / volume) with CFA before use. A final concentration of 1 g of immunogen was used per animal for the first immunization, the second, third, and fourth immunizations. For the 2nd, 4th, 5th and 6th immunizations, the protein was diluted in PBS, etc. The antibodies were pooled in molar amounts and diluted 1:1 ( The blood samples were mixed in a volume / volume ratio of 100 μg of immunogen per animal. The third, fourth, fifth and sixth doses were administered at 2-week intervals in tubes covered with DTA. Following vaccination, animals were harvested 5, 6 and 7 days after immunization.

[0197] Example 3 Immunogen coating / cell preparation The fusion proteins used for immunization are plated on the surface of cell culture 6-well plates. 8μg / 10cm in BS 2 The plates were coated with 100 μg / ml of 10 ... The cell line BT-474 (DSMZ ACC 64) was seeded on the cell surface of One day before, cells were cultured in DMEM + 5% FCS until they reached approximately 90% confluence after 24 hours. The seeds were sown at different densities.

[0198] Isolation of peripheral blood mononuclear cells from rabbits PBMCs were isolated from whole blood of immunized rabbits. The blood was diluted 1:1 with PBS. and coated with Lympholyte® according to the manufacturer's instructions (Cedarlane, CL Peripheral blood mononuclear cells (PBMCs) were stratified according to the density gradient centrifugation (80 The cells were separated from the red blood cells by centrifugation at 100 × g for 20 min at room temperature. The cells were removed from the interface and washed with PBS. (800 × g, 10 min) and suspended in RPMI 1640-based cell culture medium. It was unclear.

[0199] Monocyte removal PBMCs were incubated in cell culture medium on the plastic. The lymphocytes were harvested after the incubation period.

[0200] Enrichment of antigen-specific cells Antigen-specific lymphocytes were cultured on plates coated with the immunogen or on BT-474 cells. Lymphocytes were directly enriched with PBS. Nonspecific cells were removed by washing the lymphocytes twice with PBS. , still 10cm 2 1x10 ... The detached cells were incubated for 10 min. The cells were harvested in cell culture medium.

[0201] Single-cell sorting of immunoglobulin G-secreting lymphocytes PBMC / lymphocytes were bound to FITC (fluorescein isothiocyanate isomer 1) Stained with combined goat anti-rabbit IgG antibody (Abd Serotec, STAR121F) Flow cytometric analysis and single cell sorting were performed using a FACS cytometer. A single positive lymphocyte was detected using 3.0 × 10 6 EL-4 exposed to light Sorting was performed directly into 200 μl of cell culture medium overlying B5 feeder cells. The cell culture medium was supplemented with 5% rabbit-derived activated T cell macrophage supernatant. In the co-culture medium, 2 × 10 -6 g / ml SAC (Staphylococcus The B cells and feeder cells were fed with a solution of L. aureus (Cowan). After co-incubation, the supernatant was transferred to antibody detection and added to 100 μl of RNA isolation buffer (Qiage n, RLT).

[0202] Immunoglobulin screening via enzyme-linked immunosorbent assay For detection of secreted rabbit antibodies, the supernatant was incubated with a biotinylated capture antibody (produced in goats). The antibody was then transferred to a streptavidin microtiter plate via an anti-rabbit IgG antibody ( Overlaid with 1 μg / ml of PBS + 0.5% BSA + 0.05% Tween® ) at a final concentration of 20, and horseradish peroxidase at a final concentration of 1:7500 The analysis was performed using an anti-rabbit IgG detection antibody bound to the IgG1 antibody. The incubation was performed using PBS + 0.1% Tween® 20. 3,3',5,5'-Tetramethylbenzidine (TMB) was used as the substrate, and HCl was added. Used to stop the enzyme reaction.

[0203] Measurement of IL-1RAcP-specific antibodies in B cell supernatants The microtiter plates were incubated with IL-1RAcP and / or IL12Rβ1 protein. The cells were coated with a recombinant Fc chimeric conjugate of human IL-1RAcP or IL12Rβ1. After the blocking step, specific antibodies from the B cell supernatant bind to the target and then IL12Rβ1 binding is detected by anti-rabbit IgG antibody labeled with peroxidase (POD). The IL-1RAcP protein was used as a counterscreening. Similar to protein 1, the protein was tagged with the linker huFc and His. Antigen-specific antibodies were positive in both assays, whereas IL-1RA It bound only to cP and did not bind to IL12Rβ1.

[0204] Add 12.5 μL of IL-1RAcP protein at 0.5 μg / mL in PBS to a microtiter plate. The plates were then transferred to a 3x100 well plate, incubated, and washed three times with washing buffer. Rocking buffer was added to each well, incubated and washed. 0.5 μl of standard antibody (rabbit monoclonal antibody against IL-1RAcP, anti-IL12 Rβ1 antibody: IL-12Rβ1 antibody; GeneTex; Catalog number GTX103917 ) or a sample diluted in ELISA buffer was added, incubated, and The plate was then washed with 1:5000 POD antibody (anti-rabbit IgG in ELISA buffer). , species-specific Fab2 fragments (from donkey) conjugated to peroxidase (ECL) ; Assay dilution: 1:5000) add 12.5 μl, incubate and wash 15 μl of TMB was added, and 15 μl of HCl was added after sufficient development. Absorbance (Optical density OD) was read at 450 nm / 620 nm. The results are shown in Figure 1. ELISA buffer: PBS, 0.5% BSA, 0.05% Tween® 2 0 Washing buffer: PBS, 0.1% Tween® 20 Blocking buffer: PBS, 2% BSA, 0.05% Tween® 20 .

[0205] Example 4: Antibodies that bind to human IL-1RAcP Assay principle: NUNC Maxisorp® 384-well microtiter plates were After the blocking step, specific antibodies from the B cell supernatant were Binds to original human (P013-03) or mouse IL-1RAcP (P013-04) The antibody is then detected by a POD-labeled antibody. Samples are tested at a 1:2 dilution.

[0206] material: Plates: 384-well NUNC Maxisorp® plates; Catalog Log number 464718 protein: P013-03 (concentration 1.5mg / ml; assay concentration 0.5μg / ml) Human P013-04 (concentration 1.3mg / ml; assay concentration 0.5μg / ml) mice Standard antibody: P013-02 (concentration 1mg / ml; starting assay concentration 2μg / ml) Detection antibody: Anti-rabbit IgG, species-specific whole antibody (donkey-derived) conjugated to peroxidase (ECL); GE; Catalog No. NA9340; Assay dilution: 1:5000 PBS: Buffers in a Box, premixed PBS buffer , 10×; Roche Applied Sciences; Catalog number 116667 89001 BSA: Bovine serum albumin fraction V from bovine serum; Roche Appl ied Sciences; Catalog number 10735086001 Tween® 20: Tween® 20; Carl Roth; Catalog number 9127.2 TMB: TMB solution; Life Technologies; Catalog number SB02 HCl: 1M Titripur® hydrochloric acid; Merck; Cat. No. 10 90571000 ELISA buffer: PBS, 0.5% BSA, 0.05% Tween® Washing buffer: PBS, 0.1% Tween® Blocking buffer: PBS, 2% BSA, 0.05% Tween® Sample: Dilute 1:2 in ELISA buffer.

[0207] procedure: 1. Add 12.5 μL of P013-03 (0.5 μg / ml) in PBS to a 384-well plate Add to UNC Maxisorp® plate and ink for 1 hour at room temperature. Welcome to the new home! 2. Wash 3 times with 90 μl of wash buffer. 3. Add 90 μL of blocking buffer to each well and incubate at room temperature for 1 hour. Incubate. 4. Wash three times with wash buffer. 5. Add 12.5 μL of standard antibody (diluted 1:2 in ELISA buffer) or sample (ELISA Add 1:2 diluted ISA buffer and incubate at room temperature for 1 hour. 6. Wash three times with wash buffer. 7. Add 12.5 μL of 1:5000 POD antibody (in ELISA buffer) to the chamber. Incubate at room temperature for 1 hour. 8. Wash six times with wash buffer. 9. Add 15 μL of TMB. 10. After sufficient development, add 15 μL of HCl. 11. Read absorbance at 450nm / 620nm.

[0208] Example 5: Antibodies that bind to mouse IL-1RAcP Assay principle: NUNC Maxisorp® 384-well microtiter plates were After the blocking step, specific antibodies from the B cell supernatant were The antibody binds to the IgG1 gene and is then detected by a peroxidase-labeled antibody. Samples were tested at a 1:2 dilution. It will be tested.

[0209] material: Plates: 384-well NUNC Maxisorp® plates; Catalog Log number 464718 Protein: P013-04 (concentration 1.3 mg / ml; assay concentration 0.5 μg / ml l) Standard antibody: P013-02 (concentration 1mg / ml; starting assay concentration 2μg / ml) Detection antibody: Anti-rabbit IgG, species-specific whole antibody (donkey-derived) conjugated to peroxidase (ECL); GE; Catalog No. NA9340; Assay dilution: 1:5000 PBS: Buffers in a Box, premixed PBS buffer , 10×; Roche Applied Sciences; Catalog number 116667 89001 BSA: Bovine serum albumin fraction V from bovine serum; Roche Appl ied Sciences; Catalog number 10735086001 Tween 20: Tween® 20; Carl Roth; Catalog No. No. 9127.2 TMB: TMB solution; Life Technologies; Catalog number SB02 HCl: 1M Titripur® hydrochloric acid; Merck; Cat. No. 10 90571000 ELISA buffer: PBS, 0.5% BSA, 0.05% Tween® Washing buffer: PBS, 0.1% Tween® Blocking buffer: PBS, 2% BSA, 0.05% Tween® Sample: Dilute 1:2 in ELISA buffer.

[0210] procedure : 1. Add 12.5 μL of P013-04 (0.5 μg / ml) in PBS to a 384-well plate Add to UNC Maxisorp® plate and ink for 1 hour at room temperature. Welcome to the new home! 2. Wash 3 times with 90 μl of wash buffer. 3. Add 90 μL of blocking buffer to each well and incubate at room temperature for 1 hour. Incubate. 4. Wash three times with wash buffer. 5. Add 12.5 μL of standard antibody (diluted 1:2 in ELISA buffer) or sample (ELISA Add 1:2 diluted ISA buffer and incubate at room temperature for 1 hour. 6. Wash three times with wash buffer. 7. Add 12.5 μL of 1:5000 POD antibody (in ELISA buffer) to the chamber. Incubate at room temperature for 1 hour. 8. Wash six times with wash buffer. 9. Add 15 μL of TMB. 10. After sufficient development, add 15 μL of HCl. 11. Read absorbance at 450nm / 620nm.

[0211] Example 6: Determination of EC50 in ELISA The binding of the antibodies according to the invention to human IL-1RAcP was analyzed by ELISA: EC5 The 0 value was calculated according to conventional techniques.

[0212] Example 7: IL-1RAc in a luciferase-based gene reporter assay NF-κB neutralizing activity of antibodies against P Assay principle: 293T / 17-FR cells expressing NF-κB-RE firefly luciferase reporter The cells were seeded on poly-D-lysine-cell culture plates. After stimulation with P013, 293T NF-κB was assayed using Steady-Glo luciferase (STEAG) for activated NF-κB. The supernatant containing functional antibodies was tested using the enzyme assay kit. , inhibits NF-κB activation, as indicated by a low signal. Tested at 1:2 dilution.

[0213] material: Plates: Cell plates: 384-well PDL Costar cell culture plates; Catalog number 3844 Assay plate: 384-well Lumitrac® white plate; orning; Catalog Number 3572 Cells: 293T / 17-FR; Assay concentration 250000 cells / ml protein: P013_05 (concentration 0.03mg / ml; assay concentration 115pg / ml; working concentration 230pg / ml) IL-1α, IL-33 and IL-36 Standard antibody: P013_06 (concentration 0.2mg / ml; starting working concentration 6μg / ml) Kit: Steady-Glo Luciferase Assay System; Promega; Catalog Number E2510 Cell Culture Medium: DMEM medium; PAN Biotech; Catalog No. P04-0451 0 FCS: Fetal calf serum, HyClone; Thermo; Catalog number St3007 0.03 293T / 17-FR medium: DMEM medium, 10% FCS (+20 μg / ml high Gromycin B, for culture only) Pretreated B cell media (MAB Discovery) Sample: Dilute 1:2 with P013_05 in DMEM medium + 10% FCS.

[0214] procedure: 1. Culture confluent 293T / 17-FR cells every Monday (harvested seed cells: 5 × 10 6 cells / T175 flask) and every Friday (harvesting seed cells: 3 × 10 6 Cells / T175F Subculture with trypsin / EDTA (at room temperature for exactly 30 seconds) Incubate). 2. Dissolve cells (0.25 × 10) in 25 μl of DMEM + 10% FCS. 6 cells / ml) The cells were seeded in 384-well PDL plates (Corning Cat. No. 3844) and incubated for 3 Incubate overnight at 7° C. and 5% CO2. 3. Aspirate the medium and add the sample or P013_06 to the pretreated medium or pretreated Add 12.5 μl of the dilution, diluted 1:3 in fresh medium, and incubate at 37°C and 5% CO Incubate for 30 minutes at 2 (Program: 3 Aspiration a nd Sample transfer). 4. Add 12.5 μl of P013_05 in DMEM + 10% FCS and incubate at 37°C and Incubate for 5 hours at 5% CO2 (Program: 4_Add P013_ 05). 5. Equilibrate the cell cultures at room temperature for 10 minutes. 6. Add 25 μl of Steady-Glo® Reagent and mix several times with a pipette. (Program: 6_Steady Glo (registered trademark)). 7. After waiting 5 minutes, 45 μl of the supernatant was transferred to a 384-well Lumitrac Transfer to a white plate (Corning Catalog No. 3572) (Program: 7_ Transfer 45ul). 8. Luminescence was measured using a Tecan reader (Tecan Group Mann Measurements were taken in a 300 rpm, 100 rpm (Edorf, Switzerland): integration time: 0.5 sec.

[0215] Example 8: IL-1α Neutralization Assay material: Cells: Firefly luciferase NF-κB reporter and Renilla luciferase HEK-293T cells stably expressing IL1RAcP and IL1R-associated ... and IL1R1 are endogenously expressed Culture medium: DMEM (ATCC Catalog No. 30-2002) + 10% heat-inactivated FBS reagent: IL-1α (R&D No. 200-LA); 10 μg / ml in PBS + 0.1% BS A Anti-IL1RAcP positive control antibody (R&D No. AF676); 200 μl g / ml MAB Discovery Antibodies: Antibody on plate 1: 750 μg / ml Plate 2 antibody: 250 μg / ml Luciferase assay system (Promega no. E1500).

[0216] procedure: 1. Cells were plated at 50,000 cells / well in a 96-well plate in 100 μl of DMEM+1 Plate in 0% FBS and incubate at 37° C., 5% CO2. 2. Prepare 4-fold dilutions of antibody at 2x final concentration in DMEM + 10% FBS. 3. Cells are aspirated and antibodies are added at 2x final concentration in 60 μl of DMEM + 10% FBS. Add and incubate cells at 37° C., 5% CO 2 for 30 minutes. 4. IL-1α was added in 60 μl of complete medium at a final concentration of 175 pg / ml ( 175 pg / ml is EC50 ) and incubate at 37°C, 5% CO2 for 4 hours. 5. Wash the cells with 150 μl of PBS. 6. Dissolve the cells in 50 μl of 1x cell culture lysis reagent (based on the luciferase assay system) ) on a shaker at ambient temperature for 15 minutes. 7. Pipette up and down to load 20 μl of lysate onto the LumiTrac-200 plate. The cells were transferred to a 100 μl container, 100 μl of luciferase assay reagent was added, and luminescence was detected by Using a Wallac Victor2 with an injector or other suitable photometer Read it as follows.

[0217] Example 9: IL-1β Neutralization Assay material: Cells: Firefly luciferase NF-κB reporter and Renilla luciferase HEK-293T cells stably expressing IL1RAcP and IL1R-associated ... and IL1R1 are endogenously expressed Culture medium: DMEM (ATCC Catalog No. 30-2002) + 10% heat-inactivated FBS reagent: IL-1β (R&D No. 201-LB); 25 μg / ml in PBS + 0.1% BS A Anti-IL1RAcP positive control antibody (R&D No. AF676); 200 μl g / ml Anti-IL1RAcP rabbit pAb positive control antibody (ONCO lot AP1 4) / 200μg / ml (PBS) Normal rabbit IgG (JL No. 011-000-003); 200 μg / ml (PBS ) MAB Discovery Antibodies Antibody on plate 1: 750 μg / ml Plate 2 antibody: 250 μg / ml Luciferase assay system (Promega no. E1500).

[0218] procedure: 1. Cells were plated at 50,000 cells / well in a 96-well plate in 100 μl of DMEM+1 Plate in 0% FBS and incubate overnight at 37° C., 5% CO2. 2. Prepare 4-fold dilutions of antibody at 2x final concentration in DMEM + 10% FBS. 3. Cells are aspirated and antibodies are added at 2x final concentration in 60 μl of DMEM + 10% FBS. Add and incubate cells at 37° C., 5% CO 2 for 30 minutes. 4. IL-1β was added in 60 μl of complete medium at a final concentration of 175 pg / ml ( 175 pg / ml is EC 50 ) and incubate at 37°C, 5% CO2 for 4 hours. 5. Wash the cells with 150 μl of PBS. 6. Dissolve the cells in 50 μl of 1x cell culture lysis reagent (based on the luciferase assay system) ) on a shaker at ambient temperature for 15 minutes. 7. Pipette up and down to load 20 μl of lysate onto the LumiTrac-200 plate. The cells were transferred to a 100 μl container, 100 μl of luciferase assay reagent was added, and luminescence was detected by Using a Wallac Victor2 with an injector or other suitable photometer Read it as follows.

[0219] Example 10: IL-33 Neutralization Assay material: Cells: Firefly luciferase NF-κB receptor driven by CMV promoter Transiently stained with IL-33R, Renilla luciferase (for normalization control), and IL-33R Transfected HEK-293T cells. IL1RAcP is endogenously expressed. Can Culture medium: DMEM (ATCC Catalog No. 30-2002) + 10% heat-inactivated FBS reagent: IL-33 (R&D No. 3625-IL); 10 μg / ml in PBS + 0.1% B SA Anti-IL1RAcP positive control antibody (R&D No. AF676); 200 μl g / ml MAB Discovery Antibodies Antibody on plate 1: 750 μg / ml Plate 2 antibody: 250 μg / ml Luciferase assay system (Promega no. E1500).

[0220] procedure: 1. Plate cells at 25,000 cells / well with luciferase reporter and IL-33R. The cells are then transfected for approximately 24 hours prior to the assay. 2. Prepare 4-fold dilutions of antibody at 2x final concentration in DMEM + 10% FBS. 3. Cells are aspirated and antibodies are added at 2x final concentration in 60 μl of DMEM + 10% FBS. Add and incubate cells at 37° C., 5% CO 2 for 30 minutes. 4. IL-33 was added in 60 μl of complete medium at a final concentration of 250 pg / ml; Incubate at 37°C, 5% CO2 for 4 hours. 5. Wash the cells with 150 μl of PBS. 6. Dissolve the cells in 50 μl of 1x cell culture lysis reagent (based on the luciferase assay system) ) on a shaker at ambient temperature for 15 minutes. 7. Pipette up and down to load 20 μl of lysate onto the LumiTrac-200 plate. The cells were transferred to a 100 μl container, 100 μl of luciferase assay reagent was added, and luminescence was detected by Using a Wallac Victor2 with an injector or other suitable photometer Read it as follows.

[0221] Example 11: IL-36β (IL1F8) Neutralization Assay material: Cells: Firefly luciferase NF-κB receptor driven by CMV promoter Stable with IL-36R, Renilla luciferase (for normalization control) HEK-293T cells transfected with IL1RAcP. IL1RAcP is endogenously expressed Will be Culture medium: DMEM (ATCC Catalog No. 30-2002) + 10% heat-inactivated FBS reagent: IL-36β (R&D No. 6834-IL); 100 μg / ml in PBS+0.1% BSA Anti-IL1RAcP positive control antibody (R&D No. AF676); 200 μl g / ml MAB Discovery Antibodies Antibody on plate 1: 750 μg / ml Plate 2 antibody: 250 μg / ml Luciferase assay system (Promega no. E1500).

[0222] procedure: 1. Cells were plated at 50,000 cells / well in a 96-well plate in 100 μl of DMEM+1 Plate in 0% FBS and incubate overnight at 37° C., 5% CO2. 2. Prepare 4-fold dilutions of antibody at 2x final concentration in DMEM + 10% FBS. 3. Cells are aspirated and antibodies are added at 2x final concentration in 60 μl of DMEM + 10% FBS. Add and incubate cells at 37° C., 5% CO 2 for 30 minutes. 4. IL-36β was added in 60 μl of complete medium at a final concentration of 15 ng / ml ( 15ng / ml is EC 50 ) and incubate at 37°C, 5% CO2 for 4 hours. 5. Wash the cells with 150 μl of PBS. 6. Dissolve the cells in 50 μl of 1x cell culture lysis reagent (based on the luciferase assay system) ) on a shaker at ambient temperature for 15 minutes. 7. Pipette up and down to load 20 μl of lysate onto the LumiTrac-200 plate. The cells were transferred to a 100 μl container, 100 μl of luciferase assay reagent was added, and luminescence was detected by Using a Wallac Victor2 with an injector or other suitable photometer Read it as follows. [Brief description of the drawings]

[0223] [Figure 1] Antibodies that bind to human and mouse IL-1RAcP. Results of the experiments described in Examples 3-6. [Diagram 2] Sequences (single letter amino acids). D, A, S, K, L, A, S mean DASKLAS. The same is true for all others in Figure 2. CDRH1: SEQ ID NO: 155 to SEQ ID NO: 231, CDRH2: SEQ ID NO: 232 to SEQ ID NO: 308, CDRH3: SEQ ID NO: 309 to SEQ ID NO: 385, CDRL1: SEQ ID NO: 386 to SEQ ID NO: 462, CDRL2: SEQ ID NO: 463 to SEQ ID NO: 539, CDRL3: SEQ ID NO: 540 to SEQ ID NO: 616. [Diagram 3] Inhibition of ligand-induced signal transduction. A summary table of the signal transduction inhibition results for the 18 most promising antibodies is shown. The experimental procedures are detailed in Examples 8-11. [Figure 4] Inhibition of ligand-induced signaling by selected antibodies. Exemplary graphs of experimental results described in Examples 8-11. Shown is the percentage of NFκB stimulation by signaling of the various ligands indicated in the title of each figure. Different colors correspond to different antibodies. Only a selection of the antibodies tested are shown. [Diagram 5] NF-κB neutralizing activity of selected antibodies against IL-1RAcP. Results of the experiments described in Example 7. The NF-κB neutralizing activity of antibodies against IL-1RAcP in a luciferase-based gene reporter assay is shown. [Figure 6] Inhibition of ligand-induced signal transduction with antibodies having preferred sequences. Results of signal transduction experiments for 19 preferred antibodies are shown. Experimental procedures are detailed in Examples 8-11.

Claims

1. 2. Use of a monoclonal antibody, a humanized antibody thereof, or an antigen-binding fragment of said monoclonal antibody or humanized antibody, which specifically binds to human IL-1RAcP, for the manufacture of a medicament, comprising: The following groups: - CDR1H of SEQ ID NO: 156, CDR2H of SEQ ID NO: 233, CDR3H of SEQ ID NO: 310, CDR1L of SEQ ID NO: 387, CDR2L of SEQ ID NO: 464 and CDR3L of SEQ ID NO: 541; - CDR1H of SEQ ID NO: 157, CDR2H of SEQ ID NO: 234, CDR3H of SEQ ID NO: 311, CDR1L of SEQ ID NO: 388, CDR2L of SEQ ID NO: 465 and CDR3L of SEQ ID NO: 542; and - CDR1H of SEQ ID NO: 158, CDR2H of SEQ ID NO: 235, CDR3H of SEQ ID NO: 312, CDR1L of SEQ ID NO: 389, CDR2L of SEQ ID NO: 466 and CDR3L of SEQ ID NO: 543; The above use, characterized in that the set comprises a set of three heavy chain CDRs and three light chain CDRs selected from:

2. The use described in claim 1, wherein the agent is for the treatment of cancer.

3. The use according to claim 2, wherein the cancer is selected from breast cancer, colon cancer, lung cancer or pancreatic cancer.

4. The monoclonal antibody is selected from the group consisting of: - VH of SEQ ID NO: 2 and VL of SEQ ID NO: 79; - VH of SEQ ID NO: 3 and VL of SEQ ID NO: 80; and - VH of SEQ ID NO: 4 and VL of SEQ ID NO: 81; A pair of heavy and light chain variable regions (VH and VL) selected from 2. Use according to claim 1 , characterized in that

5. The use according to claim 1, characterized in that the monoclonal antibody comprises a CDR1H of SEQ ID NO: 156, a CDR2H of SEQ ID NO: 233, a CDR3H of SEQ ID NO: 310, a CDR1L of SEQ ID NO: 387, a CDR2L of SEQ ID NO: 464 and a CDR3L of SEQ ID NO:

541.

6. The use according to claim 1, wherein the monoclonal antibody comprises a VH of SEQ ID NO:2 and a VL of SEQ ID NO:

79.

7. The use according to claim 1, wherein the monoclonal antibody comprises a CDR1H of SEQ ID NO: 157, a CDR2H of SEQ ID NO: 234, a CDR3H of SEQ ID NO: 311, a CDR1L of SEQ ID NO: 388, a CDR2L of SEQ ID NO: 465 and a CDR3L of SEQ ID NO:

542.

8. The use according to claim 1, wherein the monoclonal antibody comprises a VH of SEQ ID NO: 3 and a VL of SEQ ID NO:

80.

9. The use according to claim 1, wherein the monoclonal antibody comprises a CDR1H of SEQ ID NO: 158, a CDR2H of SEQ ID NO: 235, a CDR3H of SEQ ID NO: 312, a CDR1L of SEQ ID NO: 389, a CDR2L of SEQ ID NO: 466 and a CDR3L of SEQ ID NO:

543.

10. The use according to claim 1, wherein the monoclonal antibody comprises a VH of SEQ ID NO: 4 and a VL of SEQ ID NO:

81.

11. 1. Use of a humanized antibody of a monoclonal antibody that specifically binds to human IL-1RAcP for the manufacture of a medicament, the humanized antibody comprising: The following groups: - CDR1H of SEQ ID NO: 156, CDR2H of SEQ ID NO: 233, CDR3H of SEQ ID NO: 310, CDR1L of SEQ ID NO: 387, CDR2L of SEQ ID NO: 464 and CDR3L of SEQ ID NO: 541; - CDR1H of SEQ ID NO: 157, CDR2H of SEQ ID NO: 234, CDR3H of SEQ ID NO: 311, CDR1L of SEQ ID NO: 388, CDR2L of SEQ ID NO: 465 and CDR3L of SEQ ID NO: 542; and - CDR1H of SEQ ID NO: 158, CDR2H of SEQ ID NO: 235, CDR3H of SEQ ID NO: 312, CDR1L of SEQ ID NO: 389, CDR2L of SEQ ID NO: 466 and CDR3L of SEQ ID NO: 543; For a humanized antibody comprising a set of three heavy chain CDRs and three light chain CDRs selected from The use of any one of the preceding claims, wherein the conservative amino acid substitution in one of the CDRs is a cysteine ​​to serine substitution, and wherein the humanized antibody maintains the specificity of the monoclonal antibody.

12. The use of claim 11, wherein the humanized and monoclonal antibodies (i) inhibit IL-1RAcP-induced NFκB activity and / or (ii) inhibit IL-1α, IL-1β, IL-33 and / or IL-36 stimulated NFκB activity.

13. 13. The use of claim 12, wherein the humanized and monoclonal antibodies inhibit NFκB activity stimulated by a complex selected from the group consisting of IL-1β / IL-1R1 / IL-1RAcP, IL-1α / IL-1R1 / IL-1RAcP, IL-33 / ST2 / IL-1RAcP and / or IL-36 / IL-36R / IL-1RAcP.

14. The use according to any one of claims 11 to 13, wherein the humanized and monoclonal antibodies, at a concentration of 5 μg / ml, inhibit NFκB activity by 70% or more in 293T / 17 cells stimulated with 0.5 μg / ml of human IL-1α, IL-1β, IL-33 and / or IL-36.

15. The use according to claim 14, wherein the humanized and monoclonal antibodies, at a concentration of 5 μg / ml, inhibit NFκB activity by 70% or more in a mouse cell line stimulated with 0.5 μg / ml of mouse IL-1α, IL-1β, IL-33 and / or IL-36.

16. The use according to any one of claims 11 to 15, characterized in that the humanized and monoclonal antibodies contain at least the amino acid substitutions L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.

17. 20. A pharmaceutical composition comprising a pharma- ceutical acceptable carrier and a therapeutically effective amount of a monoclonal antibody, a humanized antibody thereof, or an antigen-binding fragment of said monoclonal antibody or humanized antibody according to any one of claims 1 to 16, for use in the treatment of cancer.

Citation Information

Patent Citations

  • JPP7114460B